All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 04:38:08 ON 29 MAY 2007

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 04:38:25 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2
DICTIONARY FILE UPDATES: 28 MAY 2007 HIGHEST RN 935999-19-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\posullivan\183zza.str

L1 STRUCTURE UPLOADED

=>
Uploading C:\posullivan\183zzb.str

L2 STRUCTURE UPLOADED

=>
Uploading C:\posullivan\183zzc.str

L3 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> d l3
L3 HAS NO ANSWERS
L3 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1
SAMPLE SEARCH INITIATED 04:48:25 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 24 TO ITERATE

100.0% PROCESSED 24 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 187 TO 773
PROJECTED ANSWERS: 0 TO 0

L4 0 SEA SSS SAM L1

```
=> search l1
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 04:48:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      385 TO ITERATE

100.0% PROCESSED      385 ITERATIONS                                1 ANSWERS
SEARCH TIME: 00.00.01

L5            1 SEA SSS FUL L1

=> s l2
SAMPLE SEARCH INITIATED 04:48:41 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       24 TO ITERATE

100.0% PROCESSED       24 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          187 TO      773
PROJECTED ANSWERS:               0 TO        0

L6            0 SEA SSS SAM L2

=> search l2
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 04:48:47 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      385 TO ITERATE

100.0% PROCESSED      385 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

L7            5 SEA SSS FUL L2

=> s l3
SAMPLE SEARCH INITIATED 04:48:52 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       24 TO ITERATE

100.0% PROCESSED       24 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          187 TO      773
PROJECTED ANSWERS:               0 TO        0

L8            0 SEA SSS SAM L3

=> search l3
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 04:49:05 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      385 TO ITERATE

100.0% PROCESSED      385 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L9            0 SEA SSS FUL L3

=> s l5 or l7
L10           6 L5 OR L7
```

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       523.05     523.26

FILE 'CAPLUS' ENTERED AT 04:49:26 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007  (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l10
L11           5 L10

=> d l11 fbib ab hitstr 1-5

L11  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:547250  CAPLUS
DN   143:77956
TI   Preparation of bis-aryl sulfonamides as potent modulators of chemokine
     receptors
IN   Ungashe, Solomon; Wei, Zheng; Wright, J. J.; Pennell, Andrew; Premack,
     Brett; Schall, Thomas
PA   USA
SO   U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 716,183.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 5
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
PI   US 2005137179        A1    20050623    US 2004-848836           20040519
                                             US 2002-427670P      P   20021118
                                             US 2003-716183       A2  20031118
     US 2004167113        A1    20040826    US 2003-716183           20031118
                                             US 2002-427670P      P   20021118
     CA 2505590           A1    20041007    CA 2003-2505590          20031118
                                             US 2002-427670P      P   20021118
                                             WO 2003-US37035      W   20031118
     AU 2003303942        A1    20041018    AU 2003-303942           20031118
                                             US 2002-427670P      P   20021118
                                             WO 2003-US37035      W   20031118
     EP 1567486           A2    20050831    EP 2003-816012           20031118
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                             US 2002-427670P      P   20021118
```

				WO 2003-US37035	W	20031118
JP 2006510724		T	20060330	JP 2004-569975		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
WO 2005112916		A2	20051201	WO 2005-US17501		20050518
WO 2005112916		A3	20060216			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2004-848836	A	20040519
JP 2007077166		A	20070329	JP 2006-311085		20061117
				US 2002-427670P	P	20021118
				JP 2004-553842	A3	20031117

PATENT FAMILY INFORMATION:

FAN 2004:453170

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004046092	A2	20040603	WO 2003-US36766		20031117
	WO 2004046092	A3	20040715			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2002-427670P	P	20021118
CA 2500492		A1	20040603	CA 2003-2500492		20031117
				US 2002-427670P	P	20021118
				WO 2003-US36766	W	20031117
AU 2003298661		A1	20040615	AU 2003-298661		20031117
				US 2002-427670P	P	20021118
				WO 2003-US36766	W	20031117
EP 1562940		A2	20050817	EP 2003-796416		20031117

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

				US 2002-427670P	P	20021118
				WO 2003-US36766	W	20031117
CN 1711257		A	20051221	CN 2003-80103335		20031117
				US 2002-427670P	P	20021118
JP 2006506438		T	20060223	JP 2004-553842		20031117
				US 2002-427670P	P	20021118
				WO 2003-US36766	W	20031117
CA 2505590		A1	20041007	CA 2003-2505590		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
WO 2004085384		A2	20041007	WO 2003-US37035		20031118
WO 2004085384		A3	20050203			
WO 2004085384		A8	20050324			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2002-427670P	P 20021118
AU 2003303942	A1	20041018		AU 2003-303942	20031118
				US 2002-427670P	P 20021118
				WO 2003-US37035	W 20031118
EP 1567486	A2	20050831		EP 2003-816012	20031118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

				US 2002-427670P	P 20021118
				WO 2003-US37035	W 20031118
CN 1738796	A	20060222		CN 2003-80108668	20031118
				US 2002-427670P	P 20021118
JP 2006510724	T	20060330		JP 2004-569975	20031118
				US 2002-427670P	P 20021118
				WO 2003-US37035	W 20031118
ZA 2005003663	A	20051030		ZA 2005-3663	20050506
				US 2002-427670P	P 20021118
JP 2007077166	A	20070329		JP 2006-311085	20061117
				US 2002-427670P	P 20021118
				JP 2004-553842	A3 20031117

FAN 2005:1259748

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2005112925	A1	20051201	WO 2005-US16815	20050513

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG

				US 2004-846241	A 20040513
US 2005137193	A1	20050623		US 2004-846241	20040513
				US 2002-427670P	P 20021118
				US 2003-716170	A1 20031117

FAN 2006:493928

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2006111351	A1	20060525	US 2005-255163	20051020
			US 2002-427670P	P 20021118
			US 2003-716170	A2 20031117
			US 2004-846241	A2 20040513
US 2004171654	A1	20040902	US 2003-716170	20031117
US 6939885	B2	20050906		
			US 2002-427670P	P 20021118
CA 2505590	A1	20041007	CA 2003-2505590	20031118
			US 2002-427670P	P 20021118
			WO 2003-US37035	W 20031118
AU 2003303942	A1	20041018	AU 2003-303942	20031118
			US 2002-427670P	P 20021118
			WO 2003-US37035	W 20031118
EP 1567486	A2	20050831	EP 2003-816012	20031118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
JP 2006510724	T	20060330	JP 2004-569975		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
US 2005137193	A1	20050623	US 2004-846241		20040513
			US 2002-427670P	P	20021118
			US 2003-716170	A1	20031117
US 2005165067	A1	20050728	US 2005-46565		20050127
			US 2002-427670P	P	20021118
			US 2003-716170	A1	20031117
JP 2007077166	A	20070329	JP 2006-311085		20061117
			US 2002-427670P	P	20021118
			JP 2004-553842	A3	20031117

FAN 2007:90902

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI US 2007021466	A1	20070125	US 2006-486395		20060713
			US 2002-427670P	P	20021118
			US 2003-716170	A1	20031117
			US 2004-846241	A2	20040513
US 2004171654	A1	20040902	US 2003-716170		20031117
US 6939885	B2	20050906			
			US 2002-427670P	P	20021118
CA 2505590	A1	20041007	CA 2003-2505590		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
AU 2003303942	A1	20041018	AU 2003-303942		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
EP 1567486	A2	20050831	EP 2003-816012		20031118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
JP 2006510724	T	20060330	JP 2004-569975		20031118
			US 2002-427670P	P	20021118
			WO 2003-US37035	W	20031118
US 2005137193	A1	20050623	US 2004-846241		20040513
			US 2002-427670P	P	20021118
			US 2003-716170	A1	20031117
US 2005165067	A1	20050728	US 2005-46565		20050127
			US 2002-427670P	P	20021118
			US 2003-716170	A1	20031117
JP 2007077166	A	20070329	JP 2006-311085		20061117
			US 2002-427670P	P	20021118
			JP 2004-553842	A3	20031117

OS MARPAT 143:77956

AB The title compds. I [L = CO, S, SO, SO2; X = halo, alkyl, alkenyl, etc.; Y = halo, CN, NO2, etc.; Z = halo, alkyl, alkenyl, etc.] that act as potent antagonists of chemokine receptors (CCR9), were prepared Thus, reacting (2-amino-5-chlorophenyl)(phenyl)methanone with 4-tert-butylbenzenesulfonyl chloride afforded II which showed IC50 < 100 nM in either or both of the chemotaxis assay and calcium mobilization assays. The compds. I are useful in pharmaceutical compns., methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

IT 855595-53-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-aryl benzenesulfonamides as chemokine receptor CCR9 modulators)

RN 855595-53-8 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(methylsulfonyl)- (9CI) (CA INDEX NAME)



L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1981:442562 CAPLUS
DN 95:42562
TI 2-Amino-5-mercaptobenzophenone
AU Gordiichuk, G. N.; Andronati, S. A.; Yavorskii, A. S.
CS Odessa, USSR
SO Khimicheskaya Promyshlennost, Seriya: Reaktivy i Osobo Chistye Veshchestva (1980), (6), 5-6
CODEN: KSRVDF
DT Journal
LA Russian
AB 5,2-HS(H2N)C6H3COPh was prepared in 63% yield by treatment of 5,2-F2CHS(p-MeC6H4SO2NH)C6H3COPh with H2SO4.
IT 78211-76-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with sulfuric acid)
RN 78211-76-4 CAPLUS
CN Benzenesulfonamide, N-[2-benzoyl-4-[(difluoromethyl)thio]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1969:450004 CAPLUS
DN 71:50004
TI 7-(Alkyl- or arylthio)-5-phenyl-3H-1,4-benzodiazepin-2(1H)-ones
IN Keller, Oscar; Steiger, Norbert; Sternbach, Leo H.
PA Hoffmann-La Roche Inc.
SO U.S., 9 pp. Division of U.S. 3121077, U.S. 3121075, and U.S. 3121103
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3442946	A	19690506	US 1963-331904	19631219

				CS 1960-7357	A	19611029
	US 3371085	A	19680227	US 1961-154921		19611120
				CH 1960-13489	A	19601202
				CH 1960-13490	A	19601202
				CH 1960-13491	A	19601202
				CH 1960-13492	A	19601202
				CH 1960-13493	A	19601202
				CH 1960-13494	A	19601202
				CH 1960-13495	A	19601202
				CS 1960-7357	A	19611020

PATENT FAMILY INFORMATION:

FAN 1969:37850

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 3402171	A	19680917	US 1963-326337		19631127
				CH 1960-13489	A	19601202
				CH 1960-13492	A	19601202
				CH 1960-13494	A	19601202
	US 3371085	A	19680227	US 1961-154921		19611120
				CH 1960-13489	A	19601202
				CH 1960-13490	A	19601202
				CH 1960-13491	A	19601202
				CH 1960-13492	A	19601202
				CH 1960-13493	A	19601202
				CH 1960-13494	A	19601202
				CH 1960-13495	A	19601202
				CS 1960-7357	A	19611020

FAN 1970:445551

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 3515755	A	19700602	US 1968-737861		19680618
				CH 1960-13489	A	19601202
				CH 1960-13490	A	19601202
				CH 1960-13491	A	19601202
				CH 1960-13492	A	19601202
				CH 1960-13493	A	19601202
				CH 1960-13494	A	19601202
				CH 1960-13495	A	19601202
	US 3371085	A	19680227	US 1961-154921		19611120
				CH 1960-13489	A	19601202
				CH 1960-13490	A	19601202
				CH 1960-13491	A	19601202
				CH 1960-13492	A	19601202
				CH 1960-13493	A	19601202
				CH 1960-13494	A	19601202
				CH 1960-13495	A	19601202
				CS 1960-7357	A	19611020
	US 3412086	A	19681119	US 1964-406906		19641027
				CH 1960-13490	A	19601202
				CH 1960-13492	A	19601202
				CH 1960-13493	A	19601202
				CH 1960-13494	A	19601202
				CH 1960-13495	A	19601202
	US 3427304	A	19690211	US 1967-625638		19670324
				CH 1960-13489	A	19601202
				CH 1960-13490	A	19601202
				CH 1960-13491	A	19601202
				CH 1960-13492	A	19601202
				CH 1960-13493	A	19601202
				CH 1960-13494	A	19601202
				CH 1960-13495	A	19601202

AB Division of U.S. 3,121,103 (CA 61: 5671f). The disclosure is the same but the claims are different.

IT 2317-54-6P 23193-90-0P 23280-11-7P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 2317-54-6 CAPLUS

CN p-Toluenesulfonanilide, 4'-(methylthio)-2'-(α,α,α-trifluoro-o-toluoyl)- (7CI, 8CI) (CA INDEX NAME)



RN 23193-90-0 CAPLUS

CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- (7CI, 8CI) (CA INDEX NAME)



RN 23280-11-7 CAPLUS

CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)- (7CI, 8CI) (CA INDEX NAME)



L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1964:432524 CAPLUS

DN 61:32524

OREF 61:5672d-h,5673a-c

TI Aminobenzodiazepines

IN Keller, Oscar; Steiger, Norbert; Sternbach, Leo H.

PA Hoffmann-La Roche Inc.

SO 9 pp.

DT Patent

LA Unavailable

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI US 3121075 19640211 US 1962-197853 19620528
CS 19611020

AB The title compds. are useful as sedatives, tranquilizers, muscle relaxants, and anticonvulsants. 2-Aminobenzophenone (30 g.) and 40 g. NaCNS in 100 cc. MeOH, cooled to 0° was treated dropwise with a cold solution of 9.5 cc. Br in 35 cc. cold MeOH (saturated with NaBr) and the mixture stirred (cold) for an addnl. 0.5 hr. to give the 5-thiocyanato derivative (I), m. 83-4° (dilute EtOH). I (39 g.) in 200 cc. EtOH was heated to 50° on a steam bath, treated alternately in portions with 55 g. Na2S2O4 and 250 cc. 10% NaOH warmed to 80°, cooled to 40°, treated dropwise with 20 cc. Me2SO4, and stirred 1 hr. at room temperature to give 2-amino-5-methylthiobenzophenone (II), m. 47-9° (petr. ether). II (42 g.) was heated with 40 g. glycine Et ester-HCl (III in 75 cc. C5H5N for 6 hrs. at 118-20° to give IIIa (R = Me), (IV) m. 216-18° (Me2CO). Similarly, I with EtBr gave 2-amino-5-ethylthiobenzophenone which with III gave IIIa (R = Et), m. 273° (MeCN-EtOH). Also, I with BuBr gave 2-amino-5-butyl thiobenzophenone, which with III and HCl gave IIIa.HCl (R = Bu), m. 247-9°. I with ethylene bromohydrin gave 2-amino-5hydroxyethylthiobenzophenone which with III and HCl gave IIIa.HCl (R = HOCH2CH2), m. 252-3° (decomposition). IV with 30% H2O2 gave the sulfoxide (V), m. 254° (decomposition). p-MeSO2C6H4NH2.HCl with BzCl and ZnCl2 gave 2-amino-5-methylsulfonylbenzophenone, m. 159-61°, which with III gave IV sulforte, m. 256-8°. 2-Amino-5-chlorobenzophenone with SCl gave 4-benzyl-6-chloro-2,3,1-benzothiazathiolium chloride, which with Me2SO4 gave 2-amino-5-chloro-3-methylthiobenzophenone. This with III gave 7-chloro-9-methylthio-5-phenyl-3H-1,4-benzo-diazepin-2(1H)-one, m. 189-91°. II with NH2OH.HCl gave the oxime which with ClCH2COCl gave 6-methylthio-2-chloromethyl-4-phenylquinazoline 3-oxide (VI), m. 155-6° (CH2Cl2). VI with MeNH2 gave 7-methylthio-2-methylamino-5-phenyl-3H1,4-benzodiazepine 4-oxide, m. 245-6°. Similarly, VI with NH3 gave the 2-amino analog. VI with N NaOH gave IV 4-oxide (VII), m. 191-3°. VII with PCl3 gave IV. V with SOCl2 gave IIIa.HCl (R = ClCH2), m. 258-60° (decomposition) (MeOH). Also prepared were 7-methylthio-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 221-3° (EtOH); 7-methylthio-5-(o-trifluoromethylphenyl-)3H-1,4-benzodiazepin-2(1H)-one, m. 199200° (C6H6); 1-methyl derivative of IV, m. 35-45° (hexane); 7-methylthio-4,5-dihydro-5-phenyl-3H-1,4-benzodiazepin-2(1H)one, m. 150.5-2.5° (EtOH) (the 1,4-dimethyl derivative m. 96-8°); 4,5-dihydro-1,4-dimethyl-7-methylsulfinyl-5-phenyl-3H-1,4benzodiazepin-2(1H)-one, m. 160-1°; 7-chloro-5-(2-methylthiophenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 184-5°; 7-ethylsulfinyl-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one, m. 195-6°; 7-(α-chloroethylthio)-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one HCl, 'm. 236-8° (free base m. 195-6°). The following intermediates were also prepared: 2-tosylamino-5-methylthiobenzophenone, m. 119-20° (the 5-methylsulfinyl derivative m. 168-9°); 2-amino-5-methylsulfinylbenzophenone, m. 124-6°; 5-thiocyanato-2-amino-2'-chlorobenzophenone, m. 117-19°; 2-bromoacetamido-5-methylthio-2'-chlorobenzophenone, m. 106-8° (the 2-p-tosylamino analog m. 125-6°); 2-chloro-2'-nitrobenzophenone, m. 76-9° (the 2'-amino analog m. 58-60°); 5-thiocyanato2'-trifluoromethyl-2-aminobenzophenone, m. 117-18°; 5-methylthio-2'-trifluoromethyl-2-bromoacetamidobenzophenone, m. 104-5° (the 2-aminoacetamido analog m. 77-8°; the 2-p-tosylamino analog m. 122-3°); 2-amino-2'-trifluoromethylbenzophenone, m. 94-6°; 2-bromoacetamido-5-methylthiobenzophenone, m. 114-15°; 2'-benzoyl-2-bromo-4'-bromomethylthioacetanilide, m. 144-6°; 2-amino-5-chloro-2'-fluorobenzophenone, m. 94-5° (the 2'-methylthio analog m. 100-100.5°); 2-bromoacetamido-5-chloro-2'-methylthiobenzophenone, m. 107-8° (the 2-aminoacetamido analog m. 125-6°).

IT 2317-54-6P, p-Toluenesulfonanilide, 4'-(methylthio)-2'-

(α,α,α-trifluoro-o-toluoyl)- 23193-90-0P,
p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- 23280-11-7P,
p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)-
94864-13-8P, p-Toluenesulfonanilide, 2'-(o-chlorobenzoyl)-4'-
(methylthio)-
RL: PREP (Preparation)
(preparation of)

RN 2317-54-6 CAPLUS
CN p-Toluenesulfonanilide, 4'-(methylthio)-2'-(α,α,α-trifluoro-o-toluoyl)- (7CI, 8CI) (CA INDEX NAME)



RN 23193-90-0 CAPLUS
CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- (7CI, 8CI) (CA INDEX NAME)



RN 23280-11-7 CAPLUS
CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 94864-13-8 CAPLUS
CN p-Toluenesulfonanilide, 2'-(o-chlorobenzoyl)-4'-(methylthio)- (7CI) (CA INDEX NAME)



L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1964:432523 CAPLUS
DN 61:32523
OREF 61:5671f-h,5672a-d
TI Benzodiazepines
IN Keller, Oscar; Steiger, Norbert; Sternbach, Leo H.
PA Hoffman-La Roche Inc.
SO 9 pp.
DT Patent
LA Unavailable

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 3121103		19640211	US 1962-197842	19620528
				CS	19611020
	FR M2615			FR	
	GB 986873			GB	

OS MARPAT 61:32523

AB To a suspension of 30 g. 2-aminobenzophenone and 40 g. NaSCN in 100 ml. MeOH, cooled to 0° was added dropwise a cold solution of 28.5 g. Br in 35 ml. MeOH saturated with NaBr, the mixture stirred 30 min., poured into 1 l. cold H2O, and neutralized with 110 ml. 20% aqueous Na2CO3 to give 2-amino-5-thiocyanatobenzophenone (I), m. 83-4°. To a suspension of 39 g. I in 200 ml. EtOH heated to 55° was added, alternately, portionwise, 55 g. Na2S2O4 and 250 ml. 10% aqueous NaOH, the mixture heated to 80°, cooled to 40°, 27 g. Me2SO4 added dropwise, the mixture stirred 1 hr. at room temperature, the EtOH distilled, the aqueous phase diluted with 700 ml. H2O and extracted with 4 300-ml. portions C6H6, and the C6H6 phase worked up to give 2-amino-5-methylthiobenzophenone (II), m. 47-9°. A mixture of 42 g. II, 40 g. glycine Et ester-HCl, and 75 ml. C5H5N was heated 6 hrs. at 118-20°, with replacement of C5H5N as it boiled off, and the product worked up to give 7-methylthio-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one, m. 21618°. Similarly were prepared the following III (R given): 7-ethylthio (HCl salt m. 273°) (MeCN-EtOH); 7-butylthio (HCl salt m. 247-9°); 7-hydroxyethylthio (HCl salt m. 252-3°) (decomposition); 7-methylsulfinyl (HCl salt m. 254°) (decomposition); 7-methylsulfonyl, m. 256-8°; 7-chloro-9-methylthio, m. 189-91°; 1-methyl-7-methylthio, m. 35-45°; 7-chloromethylthio (HCl salt m. 258-60°) (decomposition); 7-methylthio-4,5-dihydro, m. 150.52.5°; 7-methylthio-1,4-dimethyl-4,5-dihydro, m. 96-8°; 4,5-dihydro-1,4-dimethyl-7-methylsulfinyl, m. 160-1°; 7-methylthio (4-oxide), m. 191-3°; 1-methyl-7-methylthio (4-oxide); 7-ethylsulfinyl, m. 195-6°; 7-(α-chloroethylthio) (HCl salt m. 236-8°); and 7-(α-chloroethylthio), m. 195-6°. Also prepared were 2amino-5-methylsulfonylbenzophenone, m. 159-61°; 2-amino-5methylthiobenzophenone oxime, m. 149-50°; 6-methylthio-2chloromethyl-4-phenylquinazoline 3-oxide, m. 155-6°; 7-methylthio-2-methylamino-5-phenyl-3H-1,4-benzodiazepine 4-oxide, m. 245-6°; 7-methylthio-2-amino-5-phenyl-3H-1,4-benzodiazepine 4-oxide; 2-tosylamino-5-methylthiobenzophenone, m. 119-20°;

2-tosylamino-5-methylsulfinylbenzophenone, m. 168-9°; 2amino-5-methylsulfinylbenzophenone, m. 124-6°; 5-thiocyanato2-amino-2'-chlorobenzophenone, m. 117-19°; 5-methylthio-2amino-2'-chlorobenzophenone; 2-bromoacetamido-5-methylthio2'-chlorobenzophenone, m. 106-8°; 7-methylthio-5-(2-chlorophenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 221-3°; 2-(ptosylamino)-5-methylthio-2'-chlorobenzophenone, m. 125-6°; 2-chloro-2'-nitrobenzophenone, m. 76-9°; 2-amino-2'-chlorobenzophenone, m. 58-60°; 5-thiocyanato-2'-trifluoromethyl-2aminobenzophenone, m. 117-18°; 5-methylthio-2'-trifluoromethyl-2-aminobenzophenone; 5-methylthio-2'-trifluoromethyl2-bromoacetamidobenzophenone, m. 104-5°; 5-methylthio-2'trifluoromethyl-2-aminoacetamidobenzophenone, m. 77-8°; 7methylthio-5-(o-trifluoromethylphenyl)-3H-1,4-benzodiazepin2(1H)-one, m. 199-200°; 2-(p-tosylamino)-5-methylthio-2'-trifluoromethylbenzophenone, m. 122-3° 2-amino-2'-trifluoromethylbenzophenone, m. 94-6°; 2-bromoacetamido-5-methylthiobenzophenone, m. 114-15°; 2'-benzoyl-2-bromo-4'-bromomethylthioacetanilide, m. 144-6°; 2-amino-5-chloro-2'-fluorobenzophenone, m. 94-5°; 2-amino-5-chloro-2'-methylthiobenzophenone, m. 100-100.5°; 2-bromoacetamido-2'-methylthio-5-chlorobenzophenone, m. 107-8°; 2-aminoacetamido-2'methylthio-5-chlorobenzophenone, m. 125-6°; and 7-chloro-5(2-methylthiophenyl)-3H-1,4-benzodiazepin-2(1H)-one, m. 1845°.

IT 2317-54-6P, p-Toluenesulfonanilide, 4'-(methylthio)-2'-(α,α,α-trifluoro-o-toluoyl)- 23193-90-0P, p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- 23280-11-7P, p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)- 94864-13-8P, p-Toluenesulfonanilide, 2'-(o-chlorobenzoyl)-4'-(methylthio)-
RL: PREP (Preparation)
(preparation of)

RN 2317-54-6 CAPLUS

CN p-Toluenesulfonanilide, 4'-(methylthio)-2'-(α,α,α-trifluoro-o-toluoyl)- (7CI, 8CI) (CA INDEX NAME)



RN 23193-90-0 CAPLUS

CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylthio)- (7CI, 8CI) (CA INDEX NAME)



RN 23280-11-7 CAPLUS
CN p-Toluenesulfonanilide, 2'-benzoyl-4'-(methylsulfinyl)- (7CI, 8CI) (CA INDEX NAME)



RN 94864-13-8 CAPLUS
CN p-Toluenesulfonanilide, 2'-(o-chlorobenzoyl)-4'-(methylthio)- (7CI) (CA INDEX NAME)



=>
Uploading C:\posullivan\183zzd.str

L12 STRUCTURE UPLOADED

=>
Uploading C:\posullivan\183zze.str

L13 STRUCTURE UPLOADED

=>
Uploading C:\posullivan\183zzf.str

L14 STRUCTURE UPLOADED

=> s l12
REG1stRY INITIATED
Substance data SEARCH and crossover from CAS REGISTRY in progress...
Use DISPLAY HITSTR (or FHITSTR) to directly view retrieved structures.

SAMPLE SEARCH INITIATED 05:03:20 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 91 TO ITERATE

100.0% PROCESSED 91 ITERATIONS 1 ANSWERS

```
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1248 TO     2392
PROJECTED ANSWERS:               1 TO       80

L15           1 SEA SSS SAM L12



L16          1 L15

=> file reg
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.47     575.24

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -3.90

FILE 'REGISTRY' ENTERED AT 05:03:24 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   28 MAY 2007  HIGHEST RN 935999-19-2
DICTIONARY FILE UPDATES:  28 MAY 2007  HIGHEST RN 935999-19-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> d his

     (FILE 'HOME' ENTERED AT 04:38:08 ON 29 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 04:38:25 ON 29 MAY 2007
L1                STRUCTURE UPLOADED
L2                STRUCTURE UPLOADED
L3                STRUCTURE UPLOADED
L4             0 S L1
L5             1 SEARCH L1 FULL
L6             0 S L2
L7             5 SEARCH L2 FULL
L8             0 S L3
L9             0 SEARCH L3 FULL
L10            6 S L5 OR L7

     FILE 'CAPLUS' ENTERED AT 04:49:26 ON 29 MAY 2007
```

```
L11             5 S L10
L12               STRUCTURE UPLOADED
L13               STRUCTURE UPLOADED
L14               STRUCTURE UPLOADED
                  S L12

     FILE 'REGISTRY' ENTERED AT 05:03:20 ON 29 MAY 2007
L15             1 S L12

     FILE 'CAPLUS' ENTERED AT 05:03:20 ON 29 MAY 2007
L16             1 S L15

     FILE 'REGISTRY' ENTERED AT 05:03:24 ON 29 MAY 2007

=> s l13
SAMPLE SEARCH INITIATED 05:03:44 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       91 TO ITERATE

100.0% PROCESSED       91 ITERATIONS                                 17 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1248 TO     2392
PROJECTED ANSWERS:              93 TO      587

L17           17 SEA SSS SAM L13

=> s l14
SAMPLE SEARCH INITIATED 05:03:47 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       91 TO ITERATE

100.0% PROCESSED       91 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1248 TO     2392
PROJECTED ANSWERS:               0 TO        0

L18             0 SEA SSS SAM L14

=> search l12
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 05:03:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1737 TO ITERATE

100.0% PROCESSED     1737 ITERATIONS                                 2 ANSWERS
SEARCH TIME: 00.00.01

L19             2 SEA SSS FUL L12

=> search l13
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 05:04:09 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1737 TO ITERATE

100.0% PROCESSED     1737 ITERATIONS                               287 ANSWERS
SEARCH TIME: 00.00.01

L20           287 SEA SSS FUL L13
```

```
=> s l14
SAMPLE SEARCH INITIATED 05:04:19 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       91 TO ITERATE

100.0% PROCESSED       91 ITERATIONS                                  0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:         1248 TO     2392
PROJECTED ANSWERS:               0 TO        0

L21           0 SEA SSS SAM L14

=> search l14
ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:.
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:full
FULL SEARCH INITIATED 05:04:28 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1737 TO ITERATE

100.0% PROCESSED     1737 ITERATIONS                                 18 ANSWERS
SEARCH TIME: 00.00.01

L22          18 SEA SSS FUL L14

=> d his

     (FILE 'HOME' ENTERED AT 04:38:08 ON 29 MAY 2007)

     FILE 'REGISTRY' ENTERED AT 04:38:25 ON 29 MAY 2007
L1               STRUCTURE UPLOADED
L2               STRUCTURE UPLOADED
L3               STRUCTURE UPLOADED
L4             0 S L1
L5             1 SEARCH L1 FULL
L6             0 S L2
L7             5 SEARCH L2 FULL
L8             0 S L3
L9             0 SEARCH L3 FULL
L10            6 S L5 OR L7

     FILE 'CAPLUS' ENTERED AT 04:49:26 ON 29 MAY 2007
L11            5 S L10
L12              STRUCTURE UPLOADED
L13              STRUCTURE UPLOADED
L14              STRUCTURE UPLOADED
                 S L12

     FILE 'REGISTRY' ENTERED AT 05:03:20 ON 29 MAY 2007
L15            1 S L12

     FILE 'CAPLUS' ENTERED AT 05:03:20 ON 29 MAY 2007
L16            1 S L15

     FILE 'REGISTRY' ENTERED AT 05:03:24 ON 29 MAY 2007
L17           17 S L13
L18            0 S L14
L19            2 SEARCH L12 FULL
L20          287 SEARCH L13 FULL
L21            0 S L14
L22           18 SEARCH L14 FULL

=> s l19 or l20 or l22
L23         305 L19 OR L20 OR L22
```

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                       515.85    1091.09

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -3.90

FILE 'CAPLUS' ENTERED AT 05:04:52 ON 29 MAY 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 29 May 2007  VOL 146 ISS 23
FILE LAST UPDATED: 28 May 2007  (20070528/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l23
L24         21 L23

=> d l24 fbib ab hitstr 1-21

L24  ANSWER 1 OF 21  CAPLUS  COPYRIGHT 2007 ACS on STN
AN   2005:547250  CAPLUS
DN   143:77956
TI   Preparation of bis-aryl sulfonamides as potent modulators of chemokine
     receptors
IN   Ungashe, Solomon; Wei, Zheng; Wright, J. J.; Pennell, Andrew; Premack,
     Brett; Schall, Thomas
PA   USA
SO   U.S. Pat. Appl. Publ., 56 pp., Cont.-in-part of U.S. Ser. No. 716,183.
     CODEN: USXXCO
DT   Patent
LA   English
FAN.CNT 5
     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    --------------------     --------
PI   US 2005137179       A1     20050623    US 2004-848836           20040519
                                            US 2002-427670P     P    20021118
                                            US 2003-716183      A2   20031118
     US 2004167113       A1     20040826    US 2003-716183           20031118
                                            US 2002-427670P     P    20021118
     CA 2505590          A1     20041007    CA 2003-2505590          20031118
                                            US 2002-427670P     P    20021118
                                            WO 2003-US37035     W    20031118
     AU 2003303942       A1     20041018    AU 2003-303942           20031118
                                            US 2002-427670P     P    20021118
```

				WO 2003-US37035	W	20031118
EP 1567486		A2	20050831	EP 2003-816012		20031118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
JP 2006510724		T	20060330	JP 2004-569975		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
WO 2005112916		A2	20051201	WO 2005-US17501		20050518
WO 2005112916		A3	20060216			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW						
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG						
				US 2004-848836	A	20040519
JP 2007077166		A	20070329	JP 2006-311085		20061117
				US 2002-427670P	P	20021118
				JP 2004-553842	A3	20031117

PATENT FAMILY INFORMATION:

FAN 2004:453170

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2004046092	A2	20040603	WO 2003-US36766		20031117
	WO 2004046092	A3	20040715			
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2002-427670P	P	20021118
	CA 2500492	A1	20040603	CA 2003-2500492		20031117
				US 2002-427670P	P	20021118
				WO 2003-US36766	W	20031117
	AU 2003298661	A1	20040615	AU 2003-298661		20031117
				US 2002-427670P	P	20021118
				WO 2003-US36766	W	20031117
	EP 1562940	A2	20050817	EP 2003-796416		20031117
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				US 2002-427670P	P	20021118
				WO 2003-US36766	W	20031117
	CN 1711257	A	20051221	CN 2003-80103335		20031117
				US 2002-427670P	P	20021118
	JP 2006506438	T	20060223	JP 2004-553842		20031117
				US 2002-427670P	P	20021118
				WO 2003-US36766	W	20031117
	CA 2505590	A1	20041007	CA 2003-2505590		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	WO 2004085384	A2	20041007	WO 2003-US37035		20031118

```
     WO 2004085384          A3     20050203
     WO 2004085384          A8     20050324
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
             NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
                                            US 2002-427670P     P  20021118
     AU 2003303942          A1     20041018    AU 2003-303942         20031118
                                            US 2002-427670P     P  20021118
                                            WO 2003-US37035     W  20031118
     EP 1567486             A2     20050831    EP 2003-816012         20031118
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
                                            US 2002-427670P     P  20021118
                                            WO 2003-US37035     W  20031118
     CN 1738796             A      20060222    CN 2003-80108668       20031118
                                            US 2002-427670P     P  20021118
     JP 2006510724          T      20060330    JP 2004-569975         20031118
                                            US 2002-427670P     P  20021118
                                            WO 2003-US37035     W  20031118
     ZA 2005003663          A      20051030    ZA 2005-3663           20050506
                                            US 2002-427670P     P  20021118
     JP 2007077166          A      20070329    JP 2006-311085         20061117
                                            US 2002-427670P     P  20021118
                                            JP 2004-553842      A3 20031117

FAN  2005:1259748
     PATENT NO.             KIND   DATE        APPLICATION NO.          DATE
     ---------------        ----   --------    --------------------     --------
PI   WO 2005112925          A1     20051201    WO 2005-US16815          20050513
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
             NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
             SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
             ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
             MR, NE, SN, TD, TG
                                            US 2004-846241      A  20040513
     US 2005137193          A1     20050623    US 2004-846241         20040513
                                            US 2002-427670P     P  20021118
                                            US 2003-716170      A1 20031117

FAN  2006:493928
     PATENT NO.             KIND   DATE        APPLICATION NO.          DATE
     ---------------        ----   --------    --------------------     --------
PI   US 2006111351          A1     20060525    US 2005-255163           20051020
                                            US 2002-427670P     P  20021118
                                            US 2003-716170      A2 20031117
                                            US 2004-846241      A2 20040513
     US 2004171654          A1     20040902    US 2003-716170         20031117
     US 6939885             B2     20050906
                                            US 2002-427670P     P  20021118
     CA 2505590             A1     20041007    CA 2003-2505590        20031118
                                            US 2002-427670P     P  20021118
                                            WO 2003-US37035     W  20031118
```

	AU 2003303942	A1	20041018	AU 2003-303942		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	EP 1567486	A2	20050831	EP 2003-816012		20031118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	JP 2006510724	T	20060330	JP 2004-569975		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	US 2005137193	A1	20050623	US 2004-846241		20040513
				US 2002-427670P	P	20021118
				US 2003-716170	A1	20031117
	US 2005165067	A1	20050728	US 2005-46565		20050127
				US 2002-427670P	P	20021118
				US 2003-716170	A1	20031117
	JP 2007077166	A	20070329	JP 2006-311085		20061117
				US 2002-427670P	P	20021118
				JP 2004-553842	A3	20031117
FAN	2007:90902					
	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
	---	---	---	---	---	---
PI	US 2007021466	A1	20070125	US 2006-486395		20060713
				US 2002-427670P	P	20021118
				US 2003-716170	A1	20031117
				US 2004-846241	A2	20040513
	US 2004171654	A1	20040902	US 2003-716170		20031117
	US 6939885	B2	20050906			
				US 2002-427670P	P	20021118
	CA 2505590	A1	20041007	CA 2003-2505590		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	AU 2003303942	A1	20041018	AU 2003-303942		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	EP 1567486	A2	20050831	EP 2003-816012		20031118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	JP 2006510724	T	20060330	JP 2004-569975		20031118
				US 2002-427670P	P	20021118
				WO 2003-US37035	W	20031118
	US 2005137193	A1	20050623	US 2004-846241		20040513
				US 2002-427670P	P	20021118
				US 2003-716170	A1	20031117
	US 2005165067	A1	20050728	US 2005-46565		20050127
				US 2002-427670P	P	20021118
				US 2003-716170	A1	20031117
	JP 2007077166	A	20070329	JP 2006-311085		20061117
				US 2002-427670P	P	20021118
				JP 2004-553842	A3	20031117

OS MARPAT 143:77956

AB The title compds. I [L = CO, S, SO, SO2; X = halo, alkyl, alkenyl, etc.; Y = halo, CN, NO2, etc.; Z = halo, alkyl, alkenyl, etc.] that act as potent antagonists of chemokine receptors (CCR9), were prepared Thus, reacting (2-amino-5-chlorophenyl)(phenyl)methanone with 4-tert-butylbenzenesulfonyl chloride afforded II which showed IC50 < 100 nM in either or both of the chemotaxis assay and calcium mobilization assays. The compds. I are useful in pharmaceutical compns., methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.

IT 392305-40-7P 855595-43-6P 855595-65-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-aryl benzenesulfonamides as chemokine receptor CCR9 modulators)

RN 392305-40-7 CAPLUS
CN Acetamide, N-[4-[[(2-benzoyl-4-chlorophenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 855595-43-6 CAPLUS
CN Acetamide, N-[4-[[(2-benzoyl-4-chlorophenyl)amino]sulfonyl]-2-chlorophenyl]- (9CI) (CA INDEX NAME)



RN 855595-65-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(3-pyridinylamino)- (9CI) (CA INDEX NAME)



L24 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2005:55027 CAPLUS
DN 142:155671
TI Preparation of arylsulfonamides for treating pain and inflammation associated with the bradykinin B1 pathway
IN Anthony, Neville J.; Lim, John Jin; Su, Dai-Shi; Wood, Michael R.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005004810	A2	20050120	WO 2004-US21018	20040630
	WO 2005004810	A3	20060824		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

				US 2003-484498P	P 20030702
	EP 1643960	A2	20060412	EP 2004-756434	20040630

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

				US 2003-484498P	P 20030702
				WO 2004-US21018	W 20040630
	US 2006142612	A1	20060629	US 2005-561319	20051220
				US 2003-484498P	P 20030702
				WO 2004-US21018	W 20040630

OS CASREACT 142:155671; MARPAT 142:155671

AB The title compds. I [A = O, CO, S, N5, CRbRc; D = COR4, (un)substituted CONH2, SO2NH2, ester group; X, Y, Z = N, C; with the proviso that 0-3 X, 0-3 Y and 0-3 Z are ring N atoms; R11, R12 = H, halo, alkyl, etc.; R2, R3 = H, halo, CN, NO2, etc.; R4 = H, alkyl, cycloalkyl, etc.; R5 = H, alkyl, arylalkyl, etc.; Rb, Rc = H, halo, alkyl, haloalkyl; with the proviso] which are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway (no data), were prepared and formulated. E.g., a 3-step synthesis of II, starting from Me 2-mercaptobenzoate and 1-fluoro-2-nitrobenzene, was given.

IT 827576-84-1P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of arylsulfonamides for treating pain and inflammation associated with the bradykinin B1 pathway)

RN 827576-84-1 CAPLUS

CN Butanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-chloro- (9CI) (CA INDEX NAME)



IT 827575-66-6P 827575-68-8P 827575-99-5P
827576-00-1P 827576-01-2P 827576-02-3P
827576-03-4P 827576-04-5P 827576-05-6P
827576-06-7P 827576-07-8P 827576-08-9P
827576-09-0P 827576-10-3P 827576-11-4P
827576-12-5P 827576-13-6P 827576-14-7P

827576-15-8P 827576-16-9P 827576-17-0P
827576-19-2P 827576-20-5P 827576-21-6P
827576-22-7P 827576-23-8P 827576-24-9P
827576-25-0P 827576-26-1P 827576-27-2P
827576-28-3P 827576-29-4P 827576-30-7P
827576-31-8P 827576-32-9P 827576-33-0P
827576-34-1P 827576-35-2P 827576-36-3P
827576-37-4P 827576-38-5P 827576-39-6P
827576-40-9P 827576-41-0P 827576-42-1P
827576-43-2P 827576-44-3P 827576-45-4P
827576-46-5P 827576-47-6P 827576-48-7P
827576-49-8P 827576-50-1P 827576-51-2P
827576-52-3P 827576-53-4P 827576-54-5P
827576-55-6P 827576-56-7P 827576-57-8P
827576-58-9P 827576-59-0P 827576-60-3P
827576-61-4P 827576-62-5P 827576-63-6P
827576-64-7P 827576-65-8P 827576-66-9P
827576-67-0P 827576-68-1P 827576-69-2P
827576-70-5P 827576-71-6P 827576-72-7P
827576-73-8P 827576-75-0P 827576-76-1P
827576-77-2P 827576-78-3P 827576-79-4P
827576-80-7P 827576-81-8P 827576-82-9P
827576-83-0P 827576-85-2P 827576-86-3P
827576-87-4P 827576-88-5P 827576-89-6P
827576-90-9P 827576-91-0P 827576-92-1P
827576-93-2P 827576-94-3P 827576-95-4P
827576-96-5P 827576-97-6P 827576-98-7P
827576-99-8P 827577-01-5P 827577-08-2P
827577-10-6P 827577-11-7P 827577-13-9P
827577-14-0P 827577-23-1P 827577-25-3P
827577-29-7P 827577-30-0P 827577-35-5P
827577-36-6P 827577-37-7P 827577-38-8P
827577-39-9P 827577-40-2P 827577-41-3P
827577-42-4P 827577-43-5P 827577-44-6P
827577-45-7P 827577-46-8P 827577-47-9P
827577-48-0P 827577-49-1P 827577-50-4P
827577-51-5P 827577-52-6P 827577-53-7P
827577-54-8P 827577-55-9P 827577-56-0P
827577-57-1P 827577-58-2P 827577-59-3P
827577-60-6P 827577-61-7P 827577-62-8P
827577-63-9P 827577-64-0P 827577-65-1P
827577-66-2P 827577-67-3P 827577-68-4P
827577-69-5P 827577-70-8P 827577-71-9P
827577-72-0P 827577-73-1P 827577-74-2P
827577-75-3P 827577-76-4P 827577-77-5P
827577-78-6P 827577-79-7P 827577-80-0P
827577-81-1P 827578-26-7P 827578-27-8P
827578-28-9P 827578-29-0P 827578-30-3P
827578-31-4P 827578-32-5P 827578-33-6P
827578-35-8P 827578-36-9P 827578-37-0P
827578-38-1P 827578-39-2P 827578-40-5P
827578-41-6P 827578-43-8P 827578-44-9P
827578-45-0P 827578-46-1P 827578-49-4P
827578-50-7P 827578-51-8P 827578-61-0P
827578-62-1P 827578-63-2P 827578-64-3P
827578-65-4P 827578-66-5P 827578-67-6P
827578-68-7P 827578-69-8P 827578-70-1P
827578-71-2P 827578-72-3P 827578-73-4P
827578-74-5P 827578-75-6P 827578-77-8P
827578-78-9P 827578-79-0P 827578-80-3P
827578-81-4P 827578-82-5P 827578-83-6P
827578-84-7P 827578-85-8P 827578-86-9P
827578-87-0P 827578-88-1P 827578-89-2P
827578-90-5P 827578-91-6P 827578-92-7P

827578-93-8P 827578-94-9P 827578-95-0P
827578-96-1P 827578-97-2P 827578-98-3P
827578-99-4P 827579-00-0P 827579-01-1P
827579-02-2P 827579-03-3P 827579-04-4P
827579-05-5P 827579-06-6P 827579-07-7P
827579-08-8P 827579-09-9P 827579-10-2P
827579-11-3P 827579-12-4P 827579-13-5P
827579-14-6P 827579-15-7P 827579-16-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonamides for treating pain and inflammation associated
with the bradykinin B1 pathway)

RN 827575-66-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[3-(1-piperidinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827575-68-8 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (tetrahydro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)



RN 827575-99-5 CAPLUS
CN Carbamic acid, [1-[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-3-pyrrolidinyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827576-00-1 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-01-2 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-
(2-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827576-02-3 CAPLUS
CN Carbamic acid, [1-[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-3-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827576-03-4 CAPLUS
CN 1-Piperidinecarboxamide, 3-amino-N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-04-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 827576-05-6 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 827576-06-7 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 827576-07-8 CAPLUS
CN 1-Pyrrolidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-(methylamino)- (9CI) (CA INDEX NAME)



RN 827576-08-9 CAPLUS
CN 1-Piperazinecarboxamide, 4-acetyl-N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-09-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827576-10-3 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 827576-11-4 CAPLUS
CN 4-Morpholinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-12-5 CAPLUS
CN 1-Piperidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-oxo- (9CI) (CA INDEX NAME)



RN 827576-13-6 CAPLUS
CN 1-Piperazinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-phenyl- (9CI) (CA INDEX NAME)



RN 827576-14-7 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-hydroxy-γ-oxo- (9CI) (CA INDEX NAME)



RN 827576-15-8 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-16-9 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-
hydroxy- (9CI) (CA INDEX NAME)



RN 827576-17-0 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-
hydroxy-γ-oxo- (9CI) (CA INDEX NAME)



RN 827576-19-2 CAPLUS
CN 1-Piperidinepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-22-7 CAPLUS
CN 1-Pyrrolidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-γ-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827576-23-8 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-γ,4-dioxo- (9CI) (CA INDEX NAME)



RN 827576-20-5 CAPLUS
CN 1-Pyrrolidinepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827576-21-6 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-fluoro-γ-oxo- (9CI) (CA INDEX NAME)



RN 827576-24-9 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 827576-25-0 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-γ-oxo- (9CI) (CA INDEX NAME)



RN 827576-26-1 CAPLUS
CN 1-Piperidinepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-hydroxy- (9CI) (CA INDEX NAME)



RN 827576-27-2 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,3-difluoro-γ-oxo- (9CI) (CA INDEX NAME)



RN 827576-28-3 CAPLUS
CN 1-Piperidinepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 827576-29-4 CAPLUS
CN 1-Piperidinepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-hydroxy- (9CI) (CA INDEX NAME)



RN 827576-30-7 CAPLUS
CN 4-Morpholinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-γ-oxo- (9CI) (CA INDEX NAME)



RN 827576-31-8 CAPLUS
CN 4-Morpholinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-32-9 CAPLUS
CN 1-Piperidinepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-fluoro- (9CI) (CA INDEX NAME)



RN 827576-33-0 CAPLUS
CN 1-Piperidinepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 827576-34-1 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 827576-35-2 CAPLUS
CN 4-Thiomorpholinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-γ-oxo-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 827576-36-3 CAPLUS
CN 1-Piperidinebutanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-γ,3-dioxo- (9CI) (CA INDEX NAME)



RN 827576-37-4 CAPLUS
CN 2-Morpholinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 827576-38-5 CAPLUS
CN 3-Isoxazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-cyclopropyl- (9CI) (CA INDEX NAME)



RN 827576-39-6 CAPLUS
CN Imidazo[2,1-b]thiazole-6-acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-40-9 CAPLUS
CN 3-Isoxazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 827576-41-0 CAPLUS
CN 5-Isoxazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 827576-42-1 CAPLUS
CN 2-Furanacetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 827576-43-2 CAPLUS
CN 1-Pyrrolidinepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827576-44-3 CAPLUS
CN 5-Isoxazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-phenyl- (9CI) (CA INDEX NAME)



RN 827576-45-4 CAPLUS
CN 3-Piperidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 827576-46-5 CAPLUS
CN 2-Furancarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-5-oxo-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827576-47-6 CAPLUS
CN 1-Piperidineacetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-48-7 CAPLUS
CN 3-Furancarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-2,2-dimethyl-5-oxo- (9CI) (CA INDEX NAME)



RN 827576-49-8 CAPLUS
CN 1H-Pyrazole-4-propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827576-50-1 CAPLUS
CN 1H-1,2,4-Triazole-1-propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-51-2 CAPLUS
CN 2-Furancarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827576-52-3 CAPLUS
CN 2H-Pyran-4-acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 827576-53-4 CAPLUS
CN 3-Oxazolidineacetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)





RN 827576-54-5 CAPLUS
CN 1H-Pyrazole-1-propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-55-6 CAPLUS
CN 2-Furancarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahyd
ro-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827576-56-7 CAPLUS
CN 2-Furancarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahyd
ro-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827576-57-8 CAPLUS
CN 1H-Pyrazole-1-propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 827576-58-9 CAPLUS
CN 1H-Benzimidazole-2-propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-59-0 CAPLUS
CN 1H-Pyrazole-1-propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 827576-60-3 CAPLUS
CN 1H-Benzimidazole-2-acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-61-4 CAPLUS
CN 2,1-Benzisoxazole-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-62-5 CAPLUS
CN 2-Benzothiazolepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-63-6 CAPLUS
CN 3-Furancarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 827576-64-7 CAPLUS
CN 2-Furancarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 827576-65-8 CAPLUS
CN 2-Pyrrolidineacetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 827576-66-9 CAPLUS
CN 1H-Benzimidazole-1-propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-67-0 CAPLUS
CN 4-Imidazolidineacetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2,5-dioxo- (9CI) (CA INDEX NAME)



RN 827576-68-1 CAPLUS
CN 1H-Imidazole-1-acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827576-69-2 CAPLUS
CN 1H-Indole-2-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-70-5 CAPLUS
CN 3-Pyrrolidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 827576-71-6 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 827576-72-7 CAPLUS
CN 1H-1,2,4-Triazole-1-acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-73-8 CAPLUS
CN 2-Pyrrolidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-oxo- (9CI) (CA INDEX NAME)



RN 827576-75-0 CAPLUS
CN 2H-Pyran-4-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]tetrahydro-2,2-dimethyl- (9CI) (CA INDEX NAME)



RN 827576-76-1 CAPLUS
CN Butanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4,4,4-trifluoro- (9CI) (CA INDEX NAME)



RN 827576-77-2 CAPLUS
CN Cyclohexanepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-78-3 CAPLUS
CN Butanoic acid, 4-[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]-4-oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 827576-79-4 CAPLUS
CN Propanamide, 3-amino-N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-80-7 CAPLUS
CN Propanamide, 3-(acetylamino)-N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-81-8 CAPLUS
CN Carbamic acid, [3-[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827576-82-9 CAPLUS
CN Propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-methoxy- (9CI) (CA INDEX NAME)



RN 827576-83-0 CAPLUS
CN Benzenepropanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-85-2 CAPLUS
CN Butanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-methoxy- (9CI) (CA INDEX NAME)



RN 827576-86-3 CAPLUS
CN Pentanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-chloro- (9CI) (CA INDEX NAME)



RN 827576-87-4 CAPLUS
CN Pyrazinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-88-5 CAPLUS
CN 2-Pyridinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-89-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-90-9 CAPLUS
CN 4-Pyridinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-91-0 CAPLUS
CN 5-Isoxazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-92-1 CAPLUS
CN 5-Pyrimidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827576-93-2 CAPLUS
CN Propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2,2,3,3,3-
pentafluoro- (9CI) (CA INDEX NAME)



RN 827576-94-3 CAPLUS
CN Propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,3,3-
trifluoro- (9CI) (CA INDEX NAME)



RN 827576-95-4 CAPLUS
CN Acetamide, N-[4-[[[2-(4-fluorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-96-5 CAPLUS
CN Acetamide, N-[4-[[[2-(2,3-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-97-6 CAPLUS
CN Acetamide, N-[4-[[[2-(2,4-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827576-98-7 CAPLUS
CN Acetamide, N-[4-[[[2-(3-fluorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI)
(CA INDEX NAME)



RN 827576-99-8 CAPLUS
CN Acetamide, N-[4-[[[2-(4-chlorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI)
(CA INDEX NAME)



RN 827577-01-5 CAPLUS
CN Acetamide, N-[4-[[[2-(3-chlorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI)
(CA INDEX NAME)



RN 827577-08-2 CAPLUS
CN Acetamide, N-[4-[[[2-(2-fluorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI)
(CA INDEX NAME)



RN 827577-10-6 CAPLUS
CN Acetamide, N-[4-[[[2-(3,4-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-11-7 CAPLUS
CN Acetamide, N-[4-[[[2-(4-methylbenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-13-9 CAPLUS
CN Acetamide, N-[4-[[[2-(3,5-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-14-0 CAPLUS
CN Acetamide, N-[4-[[[2-(4-nitrobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-23-1 CAPLUS
CN Acetamide, N-[4-[[[2-(2,5-difluorobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-25-3 CAPLUS
CN Acetamide, N-[4-[[[2-(4-cyanobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-29-7 CAPLUS
CN Acetamide, N-[4-[[[2-(4-hydroxybenzoyl)phenyl]amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827577-30-0 CAPLUS
CN Acetamide, N-[4-[[[2-(4-methoxybenzoyl)phenyl]amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827577-35-5 CAPLUS
CN Cyclohexanecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827577-36-6 CAPLUS
CN Cyclopentanecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-37-7 CAPLUS
CN Cyclopropanecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-38-8 CAPLUS
CN Benzamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-39-9 CAPLUS
CN Acetamide, N-[4-[[[2-[4-(trifluoromethyl)benzoyl]phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-40-2 CAPLUS
CN Acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]-2-chlorophenyl]- (9CI) (CA INDEX NAME)



RN 827577-41-3 CAPLUS
CN Acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]-2-fluorophenyl]- (9CI) (CA INDEX NAME)



RN 827577-42-4 CAPLUS
CN [1,2,4]Triazolo[1,5-a]pyrimidine-2-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-43-5 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine-2-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-44-6 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 827577-45-7 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-chloro- (9CI) (CA INDEX NAME)



RN 827577-46-8 CAPLUS
CN 1H-Pyrazole-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 827577-47-9 CAPLUS
CN Acetic acid, [[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]oxo-, methyl ester (9CI) (CA INDEX NAME)



RN 827577-48-0 CAPLUS
CN Pentanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-methyl-2-oxo- (9CI) (CA INDEX NAME)



RN 827577-49-1 CAPLUS
CN 5-Thiazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2,4-dimethyl- (9CI) (CA INDEX NAME)



RN 827577-50-4 CAPLUS
CN 4-Pyrimidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-51-5 CAPLUS
CN Acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-methoxy- (9CI) (CA INDEX NAME)



RN 827577-52-6 CAPLUS
CN Acetic acid, [[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]oxo-, (tetrahydro-2-furanyl)methyl ester (9CI) (CA INDEX NAME)



RN 827577-53-7 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-54-8 CAPLUS
CN 3-Isoxazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-55-9 CAPLUS
CN 1,2,5-Thiadiazole-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-56-0 CAPLUS
CN 1H-1,2,4-Triazole-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)



RN 827577-57-1 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827577-58-2 CAPLUS
CN 5-Thiazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-59-3 CAPLUS
CN 6-Heptynamide, N-[4-[[[2-(3-bromobenzoyl)phenyl]amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-60-6 CAPLUS
CN 4-Thiazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-61-7 CAPLUS
CN Propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-oxo- (9CI) (CA INDEX NAME)



RN 827577-62-8 CAPLUS
CN Pyrazolo[1,5-a]pyrimidine-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-63-9 CAPLUS
CN Ethanediamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-N'-methyl- (9CI) (CA INDEX NAME)



RN 827577-64-0 CAPLUS
CN 2-Pyrimidinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-65-1 CAPLUS
CN Acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 827577-66-2 CAPLUS
CN 5-Oxazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-67-3 CAPLUS
CN 1,2,5-Oxadiazole-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-68-4 CAPLUS
CN Ethanediamide, N'-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)



RN 827577-69-5 CAPLUS
CN 6-Heptynamide, N-[4-[[[2-(4-bromobenzoyl)phenyl]amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827577-70-8 CAPLUS
CN 4-Pyridazinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-
(9CI) (CA INDEX NAME)



RN 827577-71-9 CAPLUS
CN 1H-1,2,4-Triazole-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]ph
enyl]- (9CI) (CA INDEX NAME)



RN 827577-72-0 CAPLUS
CN Propanamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-2,2-dimethyl-
(9CI) (CA INDEX NAME)



RN 827577-73-1 CAPLUS
CN 1,2,5-Oxadiazole-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 827577-74-2 CAPLUS
CN 1H-Pyrazole-4-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3-methyl- (9CI) (CA INDEX NAME)



RN 827577-75-3 CAPLUS
CN 1H-Indole-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-76-4 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827577-77-5 CAPLUS
CN Benzo[b]thiophene-3-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-4,5,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 827577-78-6 CAPLUS
CN 4-Pyridazinecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,6-dichloro- (9CI) (CA INDEX NAME)



RN 827577-79-7 CAPLUS
CN 1H-Pyrazole-5-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-1-methyl- (9CI) (CA INDEX NAME)



RN 827577-80-0 CAPLUS
CN 4-Isoxazolecarboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-3,5-dimethyl- (9CI) (CA INDEX NAME)



RN 827577-81-1 CAPLUS
CN 1H-Benzimidazole-2-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 827578-26-7 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-(1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 827578-27-8 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (tetrahydro-2H-pyran-2-yl)methyl ester (9CI) (CA INDEX NAME)



RN 827578-28-9 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [4-(phenylmethyl)-2-morpholinyl]methyl ester (9CI) (CA INDEX NAME)



RN 827578-29-0 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-(3-fluoro-1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 827578-30-3 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-(4-morpholinyl)propyl ester (9CI) (CA INDEX NAME)



RN 827578-31-4 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(2R)-tetrahydro-5-oxo-2-furanyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827578-32-5 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(2R)-5-oxo-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827578-33-6 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(2S)-5-oxo-2-pyrrolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827578-35-8 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 2-(tetrahydro-2-furanyl)ethyl ester (9CI) (CA INDEX NAME)



RN 827578-36-9 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(2S)-tetrahydro-5-oxo-2-furanyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827578-37-0 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-(3,3-difluoro-1-piperidinyl)propyl ester (9CI) (CA INDEX NAME)



RN 827578-38-1 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 2-(4-morpholinyl)ethyl ester (9CI) (CA INDEX NAME)



RN 827578-39-2 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (tetrahydro-3-furanyl)methyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827578-40-5 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, [(4S)-3-(1,1-dimethylethyl)-2-oxo-4-oxazolidinyl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 827578-41-6 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (2-oxo-1,3-dioxolan-4-yl)methyl ester (9CI) (CA INDEX NAME)



RN 827578-43-8 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (2-oxo-1-pyrrolidinyl)methyl ester (9CI) (CA INDEX NAME)





RN 827578-44-9 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 2-furanylmethyl ester (9CI) (CA INDEX NAME)



RN 827578-45-0 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 7-oxabicyclo[2.2.1]hept-2-yl ester (9CI) (CA INDEX NAME)



RN 827578-46-1 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 3-phenylpropyl ester (9CI) (CA INDEX NAME)



RN 827578-49-4 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, 1,4-dioxan-2-ylmethyl ester (9CI) (CA INDEX NAME)



RN 827578-50-7 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (1-methyl-2-pyrrolidinyl)methyl ester (9CI) (CA INDEX NAME)



RN 827578-51-8 CAPLUS
CN Carbamic acid, [4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]-, (1-methyl-5-oxo-2-pyrrolidinyl)methyl ester (9CI) (CA INDEX NAME)



RN 827578-61-0 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-imidazo[1,2-a]pyridin-2-ylethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-62-1 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(1H-imidazol-4-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-63-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(1-methyl-1H-imidazol-5-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-64-3 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[3-(3-fluoro-1-piperidinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-65-4 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[3-(4-morpholinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-66-5 CAPLUS
CN Benzenesulfonamide, N-[2-(4-fluorobenzoyl)phenyl]-4-[[[[2-(1-piperidinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-67-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(5-methyl-1H-imidazol-4-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-68-7 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(1-pyrrolidinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



PAGE 2-A



RN 827578-69-8 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-pyrazinylethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-70-1 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(3-pyrrolidinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 827578-71-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1,4-dioxan-2-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-72-3 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[(tetrahydro-2H-pyran-2-yl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-73-4 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(1-piperidinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-74-5 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[3-(3,3-difluoro-1-piperidinyl)propyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-75-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-imidazo[2,1-b]thiazol-6-ylethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-77-8 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(tetrahydro-2H-pyran-4-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-78-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(tetrahydro-2-furanyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-79-0 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(3-piperidinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-80-3 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(imidazo[1,2-a]pyridin-3-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-81-4 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(4-morpholinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-82-5 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(4-pyridinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-83-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(2-pyridinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-84-7 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[(tetrahydro-2-furanyl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-85-8 CAPLUS
CN Carbamic acid, [[[4-[[[2-(4-fluorobenzoyl)phenyl]amino]sulfonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 827578-86-9 CAPLUS
CN Thiomorpholine, 4-[3-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)



RN 827578-87-0 CAPLUS

CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(tetrahydro-2H-pyran-2-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-88-1 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-pyrrolidinylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-89-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(methylamino)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-90-5 CAPLUS
CN Morpholine, 4-[3-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 827578-91-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[(tetrahydro-3-furanyl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827578-92-7 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(3-pyridinyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-93-8 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-methoxyethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-94-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(3-methoxypropyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-95-0 CAPLUS
CN Piperidine, 1-[3-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]- (9CI) (CA INDEX NAME)



RN 827578-96-1 CAPLUS
CN Glycine, N-[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827578-97-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1H-imidazol-4-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-98-3 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(imidazo[1,2-a]pyrimidin-2-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827578-99-4 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(1H-1,2,4-triazol-3-yl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-00-0 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(4-thiazolyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-01-1 CAPLUS
CN Piperidine, 1-[3-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]-3-fluoro- (9CI) (CA INDEX NAME)



RN 827579-02-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[(4-methyl-1H-imidazol-2-yl)methyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-03-3 CAPLUS
CN 2-Furancarboxamide, N-[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]tetrahydro- (9CI) (CA INDEX NAME)



RN 827579-04-4 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(3-chloropropyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-05-5 CAPLUS
CN Carbamic acid, [[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 827579-06-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[1-(phenylmethyl)-3-piperidinyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-07-7 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(imidazo[1,2-a]pyridin-2-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-08-8 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1H-1,2,4-triazol-3-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-09-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(cyclohexylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-10-2 CAPLUS
CN Piperidine, 1-[3-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-1-oxopropyl]-3,3-difluoro- (9CI) (CA INDEX NAME)



RN 827579-11-3 CAPLUS
CN Benzenesulfonamide, 4-[[[[2-(1H-benzimidazol-2-yl)ethyl]amino]carbonyl]amino]-N-(2-benzoylphenyl)- (9CI) (CA INDEX NAME)



RN 827579-12-4 CAPLUS
CN Acetamide, N-[2-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]ethyl]- (9CI) (CA INDEX NAME)



RN 827579-13-5 CAPLUS
CN 3-Piperidinamine, 1-acetyl-N-[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 827579-14-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(pyrazolo[1,5-a]pyridin-7-ylmethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827579-15-7 CAPLUS
CN β-Alanine, N-[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827579-16-8 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(3-pyridinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 827579-17-9P 827579-18-0P 827579-19-1P
827579-20-4P 827579-21-5P 827579-22-6P
827579-23-7P 827579-24-8P 827579-25-9P
827579-26-0P 827579-27-1P 827579-28-2P
827579-29-3P 827579-30-6P 827579-31-7P
827579-32-8P 827579-33-9P 827579-34-0P
827579-35-1P 827579-36-2P 828263-78-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylsulfonamides for treating pain and inflammation associated
with the bradykinin B1 pathway)

RN 827579-17-9 CAPLUS
CN Benzenesulfonamide, 4-[[[[2-(1H-benzotriazol-1-yl)ethyl]amino]carbonyl]amino]-N-(2-benzoylphenyl)- (9CI) (CA INDEX NAME)



RN 827579-18-0 CAPLUS
CN Carbamic acid, [2-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]ethyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827579-19-1 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(propylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-20-4 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(3-phenylpropyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-21-5 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 827579-22-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(dimethylamino)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-23-7 CAPLUS
CN Acetamide, 2-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-24-8 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(ethylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-25-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(2-chloroethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-26-0 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(methylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-27-1 CAPLUS
CN Acetamide, N-[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]- (9CI) (CA INDEX NAME)



RN 827579-28-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(cyclopropylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-29-3 CAPLUS
CN 1-Piperidinecarboxylic acid, 3-[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827579-30-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[[2-(4-cyanophenyl)ethyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-31-7 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(1H-indol-5-ylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-32-8 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[[(1,1-dimethylethyl)amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-33-9 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 2-[[[[[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]amino]carbonyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 827579-34-0 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(2-pyridinylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-35-1 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(1H-indol-6-

ylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 827579-36-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-[[(phenylamino)carbonyl]amino]-
(9CI) (CA INDEX NAME)



RN 828263-78-1 CAPLUS
CN 1H-1,2,3-Triazole-1-carboxamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]ph
enyl]- (9CI) (CA INDEX NAME)



IT 628301-24-6P, N-(2-Benzoylphenyl)-4-nitrobenzenesulfonamide
827579-37-3P, 4-Amino-N-(2-benzoylphenyl)benzenesulfonamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of arylsulfonamides for treating pain and inflammation
associated
with the bradykinin B1 pathway)
RN 628301-24-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-nitro- (9CI) (CA INDEX NAME)



RN 827579-37-3 CAPLUS
CN Benzenesulfonamide, 4-amino-N-(2-benzoylphenyl)- (9CI) (CA INDEX NAME)



L24 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2004:823190 CAPLUS
DN 141:332056
TI Preparation of 3-phenyl- and 3-pyridylpropenohydroxamic acid derivatives as new matrix metalloprotease (MMP-3) inhibitors
IN Hirata, Akikage; Nishimura, Hiroshi; Katayama, Kimiko; Tamura, Koichi; Amano, Hirotaka; Sugimoto, Kaori
PA Wakunaga Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 60 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 2004277311	A	20041007	JP 2003-69128	20030314
			JP 2003-69128	20030314

OS MARPAT 141:332056
AB Disclosed are matrix metalloprotease (MMP-3) inhibitors containing 3-phenyl- and 3-pyridylacrylohydroxamic acid derivs. (I) or salts thereof [wherein R1 = H, alkyl, halo; R2 = aryl, cycloalkylaryl, (un)substituted heteroaryl; R3 = H, halo; R4 = H, each (un)substituted alkyl or alkenyl; R5 = R6CO, R6SO2, R6NHCO, R6NHC(S); wherein R6 = cycloalkyl, cyclic amino, each (un)substituted alkyl, aryl, or heteroaryl; R7 = H, protecting group; A = CH, N, N(:O)] as active ingredients. These compds. are useful for the prevention and/or treatment of chronic rheumatoid arthritis, osteoarthritis (arthrosis deformans), jaw arthritis, slipped disk, venous ulcer, diabetic ulcer, bedsore, ulcerative colitis, Crohn's disease, duodenum ulcer, dystrophic blister, herpes dermatitis, yellow ligament calcareous deposition, cancer, heart attack, and stroke. Thus, 270 mg (E/Z)-3-[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(N-oxidopyridin-3-yl)propenoic acid Et ester (preparation given) was dissolved 3 mL dioxane, treated with 2 mL 5% aqueous NaOH solution, stirred at room temperature for 1 h 40 min, distilled under reduced pressure to remove dioxane, diluted with H2O, adjusted to pH 5-6 with 55 aqueous HCl solution, and extracted with EtOAc to give, after workup, an oil (0.19 g). The oil was dissolved in 1.5 mL DMF, successively treated with 1-hydroxybenzotriazole 76, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 114, N-methylmorpholine 50, and O-(tert-butyldimethylsilyl)hydroxylamine 123 mg and stirred for 22 h, treated with 5 ML, and extracted with CHCl3/THF (4:1) to give, after workup and silica gel chromatog., (E)-3-[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(N-oxidopyridin-3-yl)propenohydroxamic acid. (E)-3-[3-[N-(4-methoxybenzenesulfonyl)-N-isopropylamino]phenyl]-3-(2-pyridyl)propenohydroxamic acid showed IC50 of μg/mL against 0.030 μM against MMP-3.
IT 121779-69-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)
(preparation of 3-phenyl- and 3-pyridylpropenohydroxamic acid derivs. as new matrix metalloprotease (MMP-3) inhibitors as preventives or remedies for diseases)

RN 121779-69-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methoxy- (9CI) (CA INDEX NAME)



L24 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:950984 CAPLUS

DN 140:5067

TI Preparation of N-heteroaryl- and N-arylbenzenesulfonamide and -heterocyclesulfonamides as chemokine CCR9 inhibitors as antiinflammatory agents

IN Fleming, Paul; Harriman, Geraldine C. B.; Shi, Zhan; Chen, Shaowu

PA Millennium Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 110 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	WO 2003099773	A1	20031204	WO 2003-US16090		20030521
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
				US 2002-383573P	P	20020524
	CA 2485681	A1	20031204	CA 2003-2485681		20030521
				US 2002-383573P	P	20020524
				WO 2003-US16090	W	20030521
	AU 2003248549	A1	20031212	AU 2003-248549		20030521
				US 2002-383573P	P	20020524
				WO 2003-US16090	W	20030521
	US 2004038976	A1	20040226	US 2003-443155		20030521
				US 2002-383573P	P	20020524
	EP 1507756	A1	20050223	EP 2003-755422		20030521
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
				US 2002-383573P	P	20020524
				WO 2003-US16090	W	20030521
	JP 2005526857	T	20050908	JP 2004-507431		20030521
				US 2002-383573P	P	20020524
				WO 2003-US16090	W	20030521
	ZA 2004009131	A	20050712	ZA 2004-9131		20041111

				US 2002-383573P	P 20020524
	US 2006167251	A1	20060727	US 2006-391633	20060328
				US 2002-383573P	P 20020524
				US 2003-443155	A3 20030521
	JP 2006265259	A	20061005	JP 2006-124437	20060427
				US 2002-383573P	P 20020524
				JP 2004-507431	A3 20030521
	US 2007066823	A1	20070322	US 2006-601025	20061117
				US 2002-383573P	P 20020524
				US 2003-443155	A1 20030521

OS MARPAT 140:5067

AB The title compds. [I; Y is C(O), O, S, S(O), or S(O)2; X1, X2, and X3 are each, independently, N or CR, provided that at least one of X1, X2, or X3 is CR; R for each occurrence and R1 are each, independently, H or a substituent; R6 is H, an aliphatic carbonyl group, or an aliphatic ester; ring A is substituted or unsubstituted; and Ar1 and Ar2 are each, independently, an (un)substituted aryl or heteroaryl] or pharmaceutically acceptable salts, solvates or hydrates thereof are prepared These compds. I can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, in particular treating or preventing an inflammatory disease or condition and to the use the compds. I in research, therapeutic, prophylactic, and diagnostic methods. CCR9 and its associated chemokine TECK, have been implicated in chronic inflammatory diseases, such as inflammatory bowel diseases. Small mol. inhibitors of the interaction between CCR9 and its ligands (e.g., TECK), such as the compds. I, are useful for inhibiting harmful inflammatory processes triggered by receptor-ligand interactions and thus are useful for treating diseases mediated by CCR9, such as chronic inflammatory diseases. For example, 14 compds. including N-(2-benzoyl-4-bromophenyl)-4-methoxybenzenesulfonamide, 5-(oxazol-5-yl)thiophene-2-sulfonic acid (2-benzoyl-4-chlorophenyl)amine inhibited the binding of human TECK to human CCR9 receptors with IC50 value less than or equal to .apprx.1.0 μM.

IT 20594-91-6P 121779-69-9P 140916-44-5P
314054-02-9P 314054-05-2P 392305-40-7P
628300-37-8P 628300-42-5P 628300-47-0P
628300-73-2P 628300-93-6P 628300-94-7P
628300-99-2P 628301-03-1P 628301-07-5P
628301-21-3P 628301-24-6P 628301-38-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heteroaryl- and N-arylbenzenesulfonamide and -heterocyclesulfonamides as chemokine CCR9 inhibitors as antiinflammatory agents)

RN 20594-91-6 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-2-nitro- (9CI) (CA INDEX NAME)



RN 121779-69-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methoxy- (9CI) (CA INDEX NAME)

Continuity/Foreign Data report

Patent Number: Not Issued **Issue Date:** N/A
Title: CCR9 INHIBITORS AND METHODS OF USE THEREOF

No foreign data for this application.

Parent Data

11/391633 (in phx)	is a division of	10/443155 (in phx)
10/443155 (in phx)	Claims Priority from Provisional Application	60/383573 (in phx)

No child data for this application.



RN 140916-44-5 CAPLUS
CN Benzenesulfonamide, N-[4-chloro-2-(2-fluorobenzoyl)phenyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 314054-02-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-nitro- (9CI) (CA INDEX NAME)



RN 314054-05-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-methyl-3-nitro- (9CI) (CA INDEX NAME)



RN 392305-40-7 CAPLUS
CN Acetamide, N-[4-[[(2-benzoyl-4-chlorophenyl)amino]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)



RN 628300-37-8 CAPLUS
CN Benzenesulfonamide, N-[4-chloro-2-(2-chlorobenzoyl)phenyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 628300-42-5 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-ethyl- (9CI) (CA INDEX NAME)



RN 628300-47-0 CAPLUS
CN Benzenesulfonamide, 4-ethyl-N-[4-nitro-2-[3-(trifluoromethyl)benzoyl]phenyl]- (9CI) (CA INDEX NAME)



RN 628300-73-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-chloro- (9CI) (CA INDEX NAME)



RN 628300-93-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 628300-94-7 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 628300-99-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(ethylamino)- (9CI) (CA INDEX NAME)



RN 628301-03-1 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(diethylamino)- (9CI) (CA INDEX NAME)



RN 628301-07-5 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-(dimethylamino)- (9CI) (CA INDEX NAME)



RN 628301-21-3 CAPLUS
CN Benzenesulfonamide, N-[4-chloro-2-(2-methoxybenzoyl)phenyl]-4-nitro- (9CI) (CA INDEX NAME)



RN 628301-24-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoylphenyl)-4-nitro- (9CI) (CA INDEX NAME)



RN 628301-38-2 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2003:533368 CAPLUS
DN 139:230297
TI 1H, 13C and 15N NMR spectral and X-ray structural studies of 2-arylsulfonylamino-5-chlorobenzophenones
AU Kolehmainen, E.; Nissinen, M.; Janota, H.; Gawinecki, R.; Osmialowski, B.
CS Department of Chemistry, University of Jyvaeskylae, Jyvaeskylae, FIN-40014, Finland
SO Polish Journal of Chemistry (2003), 77(7), 889-894
CODEN: PJCHDQ; ISSN: 0137-5083
PB Polish Chemical Society
DT Journal
LA English
AB Six 2-(4-R-phenylsulfonylamino)-5-chlorobenzophenones were prepared and their 1H, 13C and 15N NMR spectra recorded and assigned. The dependence between the chemical shift of the amide proton and Hammett σ substituent consts. is of the V type. Substituent effect on the chemical shift of the amide nitrogen atom was found insignificant. X-ray anal. shows that the terminal benzene rings in 2-(4-nitrophenylsulfonylamino)-5-chlorobenzophenone are located close to each other. They are not, however, parallel, dihedral angle between them being equal to 10.86 deg (MP2/6-31G**//HF/6-31G** ab initio calcns. show this to be 20.44 deg). This shows that the mutual orientation of two benzene rings in the mol. of this compound is caused by the π-π stacking. It is addnl. reinforced by the intramol. NH···O:C hydrogen bond. Except the dihedral angle between the benzene rings, X-ray determined structure of 2-(4-nitrophenylsulfonylamino)-5-chlorobenzophenone is very similar to this optimized by the ab initio calcns.
IT 314054-02-9
RL: PRP (Properties)
(crystal structure; proton, carbon-13, and nitrogen-15 NMR and crystallog. study of 2-arylsulfonylamino-5-chlorobenzophenones)
RN 314054-02-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-4-nitro- (9CI) (CA INDEX NAME)



RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2002:171844 CAPLUS
DN 136:232200
TI Preparation of propenohydroxamic acid derivatives as TACE inhibitors for treatment of sepsis, infectious and autoimmune diseases, etc.
IN Hirata, Terukage; Misumi, Keiji; Ito, Kenji; Inokuma, Kenichi; Katayama, Kimiko
PA Wakunaga Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002018326	A1	20020307	WO 2001-JP7292	20010827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
			JP 2000-263094	A 20000831
AU 2001080167	A5	20020313	AU 2001-80167	20010827
			JP 2000-263094	A 20000831
			WO 2001-JP7292	W 20010827
CA 2423733	A1	20030214	CA 2001-2423733	20010827
			JP 2000-263094	A 20000831
			WO 2001-JP7292	W 20010827
EP 1314721	A1	20030528	EP 2001-958495	20010827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
			JP 2000-263094	A 20000831
			WO 2001-JP7292	W 20010827
US 2004029928	A1	20040212	US 2003-344898	20030226
			JP 2000-263094	A 20000831
			WO 2001-JP7292	W 20010827

OS MARPAT 136:232200
AB The title compds. I [R1 represents hydrogen, alkyl or halogeno; R2 represents cycloalkyl, aryl, heteroaryl, etc.; R3 represents hydrogen, alkenyl, etc.; R4 represents H, (un)substituted alkyl, etc.; R5 represents R6CO, R6SO2, R6NHCO or R6NHCS (wherein R6 represents alkyl, cycloalkyl, cyclic amino, aryl, heteroaryl, etc.); R7 represents hydrogen or a protective group; and A represents CH, nitrogen, etc.] are prepared I are useful as drugs for preventing and/or treating diseases such as sepsis, rheumatoid arthritis, infectious diseases, autoimmune diseases, malignant neoplasm, collagen disease, etc. E-3-[3-[N-(4-methoxybenzenesulfonyl)-N-methylaminophenyl]-3-(3-pyridyl)]propenohydroxamic acid (II) in vitro showed IC50 of 7 nM against TACE. II in vitro showed IC50 of > 10000 nM against MMP-1.
IT 121779-69-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of propenohydroxamic acid derivs. as TACE inhibitors for treatment of sepsis and infectious and autoimmune diseases)
RN 121779-69-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methoxy- (9CI) (CA INDEX NAME)



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2001:567847 CAPLUS
DN 135:304135
TI Synthesis, Molecular Modeling, and Structure-Activity Relationship of Benzophenone-Based CAAX-Peptidomimetic Farnesyltransferase Inhibitors
AU Sakowski, Jacek; Boehm, Markus; Sattler, Isabel; Dahse, Hans-Martin; Schlitzer, Martin
CS Institut fuer Pharmazeutische Chemie, Philipps-Universitaet Marburg, Marburg, D-35032, Germany
SO Journal of Medicinal Chemistry (2001), 44(18), 2886-2899
CODEN: JMCMAR; ISSN: 0022-2623
PB American Chemical Society
DT Journal
LA English
OS CASREACT 135:304135
AB Because of the involvement of farnesylated proteins in oncogenesis, inhibition of the protein-modifying enzyme farnesyltransferase is considered a major emerging strategy in cancer therapy. Here, the authors describe the structure-activity relationship of a novel class of CAAX-peptidomimetic farnesyltransferase inhibitors based on the benzophenone scaffold. 4'-Me, 4'-chloro, 4'-bromo, and 4'-nitrophenylacetic acid as substituents at the 2-amino group of the benzophenone core structure yield farnesyltransferase inhibitors active in the nanomolar range. Using diphenylacetic acid in this position further improves activity. Benzophenone-based cysteinamide I, an example of the title compds., was synthesized. SEAL superimposition of I as an inhibitor to the enzyme-bound conformation of a CAAX-peptide shows a markedly good resemblance of the mol. properties of the peptide. FlexX docking of I confirms the good fit of the mol. into the peptide binding site of farnesyltransferase. The novel benzophenone-based CAAX-peptidomimetic substructure described here will be useful for the design of some novel types of farnesyltransferase inhibitors.
IT 366456-85-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation, mol. modeling and structure-activity relationships of benzophenone-based CAAX-peptidomimetics as inhibitors of farnesyltransferase)
RN 366456-85-1 CAPLUS
CN Propanamide, 2-amino-N-[3-benzoyl-4-[[(4-methylphenyl)sulfonyl]amino]phenyl]-3-mercapto-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 366456-92-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, mol. modeling and structure-activity relationships of benzophenone-based CAAX-peptidomimetics as inhibitors of farnesyltransferase)
RN 366456-92-0 CAPLUS
CN Carbamic acid, [(1R)-2-[[3-benzoyl-4-[[(4-methylphenyl)sulfonyl]amino]phenyl]amino]-2-oxo-1-[[(triphenylmethyl)thio]methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1995:811922 CAPLUS
DN 123:285437
TI Synthesis of substituted amides and their bioactivity
AU Wu, Jingping; Chen, Fuheng
CS Department of Applied Chemistry, Beijing Agricultural University, Beijing, 100094, Peop. Rep. China
SO Yingyong Huaxue (1995), 12(4), 80-3
CODEN: YIHUED; ISSN: 1000-0518
PB Yingyong Huaxue Bianji Weiyuanhui
DT Journal
LA Chinese
AB Thirty substituted amides e.g. 2,4-RClC6H3NHXR1 (R = Bz, PhCHOH, R1 = substituted Ph; X = CO, SO2) have been synthesized from 5-chloro-2-aminobenzophenone. Most of the compds. showed an inhibition effect on rice growth.
IT 169263-22-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
(synthesis of substituted amides and their plant growth regulator activity)

RN 169263-22-3 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-3-nitro- (9CI) (CA INDEX NAME)



L24 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1995:777639 CAPLUS

DN 123:198616

TI Preparation of N-sulfonylindoline derivatives with affinity for vasopressin and oxytocin receptors

IN Wagnon, Jean; de Cointet, Paul; Nisato, Dino; Plouzane, Claude; Sereadeil-Legal, Claudine; Tonnerre, Bernard

PA Elf Sanofi SA, Fr.

SO U.S., 50 pp. Cont.-in-part of U.S. Ser. No.737,655, abandoned.
CODEN: USXXAM

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	US 5338755	A	19940816	US 1992-923839		19920803
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
	FR 2665441	A1	19920207	FR 1990-9778		19900731
	FR 2665441	B1	19921204			
	IL 114934	A	19960804	IL 1991-114934		19910730
				FR 1990-9778	A	19900731
				IL 1991-99012	A3	19910730
	HU 219351	B	20010328	HU 1971-99045		19910731
				FR 1990-9778	A	19900731
				HU 1991-2552	A	19910731
	FR 2679903	A1	19930205	FR 1991-9908		19910802
	FR 2679903	B1	19931203			
	AU 9224758	A	19930302	AU 1992-24758		19920731
	AU 658664	B2	19950427			
				FR 1991-9908	A	19910802
				WO 1992-FR758	A	19920731
	BR 9205336	A	19931116	BR 1992-5336		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	A	19920731
	JP 06501960	T	19940303	JP 1993-503337		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	RU 2104268	C1	19980210	RU 1993-5168		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	IL 117592	A	19990411	IL 1992-117592		19920731

				FR 1991-9908	A	19910802
				IL 1992-102703	A3	19920731
CZ 288173	B6	20010516		CZ 1993-682		19920731
				FR 1991-9908	A	19910802
				CS 1993-682	A	19920731
CA 2206776	C	20020226		CA 1992-2206776		19920731
				FR 1991-9908	A	19910802
				CA 1992-2093221	A3	19920731
SK 283463	B6	20030805		SK 1993-426		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
NO 9301262	A	19930526		NO 1993-1262		19930401
NO 180047	B	19961028				
NO 180047	C	19970205				
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
FI 104069	B	19991115		FI 1993-1476		19930401
FI 104069	B1	19991115				
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
US 5397801	A	19950314		US 1994-240360		19940510
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				US 1992-923839	A3	19920803
US 5481005	A	19960102		US 1994-348150		19941128
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				US 1993-923839	A3	19930803
				US 1994-240360	A3	19940510
US 5578633	A	19961126		US 1995-458614		19950602
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				US 1992-923839	A3	19920803
				US 1994-240360	A3	19940510
				US 1994-348150	A3	19941128
FI 9800175	A	19980127		FI 1998-175		19980127
FI 107048	B1	20010531				
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
				FI 1993-1476	A	19930401

PATENT FAMILY INFORMATION:

FAN 1992:214341

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 469984	A2	19920205	EP 1991-402123	19910730
	EP 469984	A3	19920311		
	EP 469984	B1	19951018		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
				FR 1990-9778	A 19900731
	FR 2665441	A1	19920207	FR 1990-9778	19900731
	FR 2665441	B1	19921204		
	FI 9103614	A	19920201	FI 1991-3614	19910729
	FI 97224	B	19960731		
	FI 97224	C	19961111		
				FR 1990-9778	A 19900731
	CA 2048139	A1	19920201	CA 1991-2048139	19910730
	CA 2048139	C	20020212		
				FR 1990-9778	A 19900731
	NO 9102970	A	19920203	NO 1991-2970	19910730
	NO 175254	B	19940613		
	NO 175254	C	19940921		

				FR 1990-9778	A	19900731
AT 129236	T	19951115		AT 1991-402123		19910730
				FR 1990-9778	A	19900731
ES 2080922	T3	19960216		ES 1991-402123		19910730
				FR 1990-9778	A	19900731
IL 99012	A	19960723		IL 1991-99012		19910730
				FR 1990-9778	A	19900731
IL 114934	A	19960804		IL 1991-114934		19910730
				FR 1990-9778	A	19900731
				IL 1991-99012	A3	19910730
AU 9181478	A	19920206		AU 1991-81478		19910731
AU 645585	B2	19940120				
				FR 1990-9778	A	19900731
ZA 9106031	A	19920429		ZA 1991-6031		19910731
				FR 1990-9778	A	19900731
HU 59669	A2	19920629		HU 1991-2552		19910731
HU 220765	B1	20020528				
				FR 1990-9778	A	19900731
JP 04234361	A	19920824		JP 1991-192078		19910731
JP 3195381	B2	20010806				
				FR 1990-9778	A	19900731
KR 211434	B1	19990802		KR 1991-13249		19910731
				FR 1990-9778	A	19900731
HU 219351	B	20010328		HU 1971-99045		19910731
				FR 1990-9778	A	19900731
				HU 1991-2552	A	19910731
AU 9350473	A	19940113		AU 1993-50473		19931105
AU 664491	B2	19951116				
				FR 1990-9778	A	19900731
US 5481005	A	19960102		US 1994-348150		19941128
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				US 1993-923839	A3	19930803
				US 1994-240360	A3	19940510

FAN 1993:539091

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	EP 526348	A1	19930203	EP 1992-402213		19920803
	EP 526348	B1	19980218			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
				FR 1991-9908	A	19910802
	FR 2679903	A1	19930205	FR 1991-9908		19910802
	FR 2679903	B1	19931203			
	CA 2093221	A1	19930203	CA 1992-2093221		19920731
	CA 2093221	C	19980922			
				FR 1991-9908	A	19910802
	WO 9303013	A1	19930218	WO 1992-FR758		19920731
	W: AU, BR, CA, CS, FI, HU, JP, KR, NO, RU					
				FR 1991-9908	A	19910802
	AU 9224758	A	19930302	AU 1992-24758		19920731
	AU 658664	B2	19950427			
				FR 1991-9908	A	19910802
				WO 1992-FR758	A	19920731
	ZA 9205781	A	19930302	ZA 1992-5781		19920731
				FR 1991-9908	A	19910802
	BR 9205336	A	19931116	BR 1992-5336		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	A	19920731
	JP 06501960	T	19940303	JP 1993-503337		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	LT 3064	B	19941025	LT 1992-114		19920731
				FR 1991-9908	A	19910802

LV 10091	B	19950420	LV 1992-87		19920731
			FR 1991-9908	A	19910802
HU 68927	A2	19950828	HU 1993-951		19920731
			FR 1991-9908	A	19910802
IL 102703	A	19970318	IL 1992-102703		19920731
			FR 1991-9908	A	19910802
JP 2633085	B2	19970723	JP 1992-503337		19920731
			FR 1991-9908	A	19910802
RU 2104268	C1	19980210	RU 1993-5168		19920731
			FR 1991-9908	A	19910802
			WO 1992-FR758	W	19920731
IL 117592	A	19990411	IL 1992-117592		19920731
			FR 1991-9908	A	19910802
			IL 1992-102703	A3	19920731
CZ 288173	B6	20010516	CZ 1993-682		19920731
			FR 1991-9908	A	19910802
			CS 1993-682	A	19920731
CA 2206776	C	20020226	CA 1992-2206776		19920731
			FR 1991-9908	A	19910802
			CA 1992-2093221	A3	19920731
SK 283463	B6	20030805	SK 1993-426		19920731
			FR 1991-9908	A	19910802
			WO 1992-FR758	W	19920731
AT 163289	T	19980315	AT 1992-402213		19920803
			FR 1991-9908	A	19910802
ES 2117038	T3	19980801	ES 1992-402213		19920803
			FR 1991-9908	A	19910802
NO 9301262	A	19930526	NO 1993-1262		19930401
NO 180047	B	19961028			
NO 180047	C	19970205			
			FR 1991-9908	A	19910802
			WO 1992-FR758	W	19920731
FI 104069	B	19991115	FI 1993-1476		19930401
FI 104069	B1	19991115			
			FR 1991-9908	A	19910802
			WO 1992-FR758	W	19920731
US 5481005	A	19960102	US 1994-348150		19941128
			FR 1990-9778	A	19900731
			US 1991-737655	B2	19910730
			FR 1991-9908	A	19910802
			US 1993-923839	A3	19930803
			US 1994-240360	A3	19940510
AU 9511541	A	19950504	AU 1995-11541		19950203
AU 691223	B2	19980514			
			FR 1991-9908	A	19910802
HU 9500474	A3	19951030	HU 1995-474		19950628
			FR 1991-9908	A	19910802
FI 9800175	A	19980127	FI 1998-175		19980127
FI 107048	B1	20010531			
			FR 1991-9908	A	19910802
			WO 1992-FR758	W	19920731
			FI 1993-1476	A	19930401

OS MARPAT 123:198616

AB Title compds. I (R'1 = halo, C1-4 alkyl, HO, C1-4 alkoxy, PhCH2O, NC, F3C, O2N, H2N; R'2 = C1-6 alkyl, C3-7 cycloalkyl, C5-7 cycloalkylene, (substituted) Ph, etc.; R'3 = H; R'4 = H2NCO, R'6R'7NCO wherein R'6R'7N = saturated 5-membered substituted N-heterocyclyl; R'5 = C1-4 alkyl, 1-, 2-naphthyl, (substituted) Ph, etc.; n = m = 0-2) or a salt thereof, are prepared CH2BrCONMe2 (preparation given) and 5-chloro-2-(tosylamino)phenyl cyclohexyl ketone were reacted to give 2-[N-tosyl-N-(dimethylcarbamoylmethyl)amino]-5-(chlorophenyl) cyclohexyl ketone which in THF was treated with Li diisopropylamide to give after workup trans-I (R'1n = 5-Cl, R'2 = cyclohexyl, R'3 = H, R'4 = Me2NCO, R'5 = 4-MeC6H4, m = 0). The IC50 of I affinity for oxytocin receptors was

10-5-10-8M.
IT 94107-57-0P 140916-44-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-sulfonylindoline derivs. with affinity for vasopressin and oxytocin receptors)
RN 94107-57-0 CAPLUS
CN Benzenesulfonamide, N-[2-(2-fluorobenzoyl)-4-nitrophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 140916-44-5 CAPLUS
CN Benzenesulfonamide, N-[4-chloro-2-(2-fluorobenzoyl)phenyl]-4-nitro- (9CI) (CA INDEX NAME)



L24 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1992:214341 CAPLUS
DN 116:214341
TI Preparation of 1-arylsulfonyl-3-hydroxyindoline-2-carboxylates and analogs as vasopressin and oxytocin receptor ligands
IN Wagnon, Jean; De Cointet, Paul; Nisato, Dino; Plouzane, Claude; Serradeil-Legal, Claudine
PA Sanofi SA, Fr.
SO Eur. Pat. Appl., 44 pp.
CODEN: EPXXDW
DT Patent
LA French
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 469984	A2	19920205	EP 1991-402123	19910730
EP 469984	A3	19920311		
EP 469984	B1	19951018		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
			FR 1990-9778 A	19900731
FR 2665441	A1	19920207	FR 1990-9778	19900731
FR 2665441	B1	19921204		
FI 9103614	A	19920201	FI 1991-3614	19910729

FI 97224	B	19960731		
FI 97224	C	19961111		
			FR 1990-9778	A 19900731
CA 2048139	A1	19920201	CA 1991-2048139	19910730
CA 2048139	C	20020212		
			FR 1990-9778	A 19900731
NO 9102970	A	19920203	NO 1991-2970	19910730
NO 175254	B	19940613		
NO 175254	C	19940921		
			FR 1990-9778	A 19900731
AT 129236	T	19951115	AT 1991-402123	19910730
			FR 1990-9778	A 19900731
ES 2080922	T3	19960216	ES 1991-402123	19910730
			FR 1990-9778	A 19900731
IL 99012	A	19960723	IL 1991-99012	19910730
			FR 1990-9778	A 19900731
IL 114934	A	19960804	IL 1991-114934	19910730
			FR 1990-9778	A 19900731
			IL 1991-99012	A3 19910730
AU 9181478	A	19920206	AU 1991-81478	19910731
AU 645585	B2	19940120		
			FR 1990-9778	A 19900731
ZA 9106031	A	19920429	ZA 1991-6031	19910731
			FR 1990-9778	A 19900731
HU 59669	A2	19920629	HU 1991-2552	19910731
HU 220765	B1	20020528		
			FR 1990-9778	A 19900731
JP 04234361	A	19920824	JP 1991-192078	19910731
JP 3195381	B2	20010806		
			FR 1990-9778	A 19900731
KR 211434	B1	19990802	KR 1991-13249	19910731
			FR 1990-9778	A 19900731
HU 219351	B	20010328	HU 1971-99045	19910731
			FR 1990-9778	A 19900731
			HU 1991-2552	A 19910731
AU 9350473	A	19940113	AU 1993-50473	19931105
AU 664491	B2	19951116		
			FR 1990-9778	A 19900731
US 5481005	A	19960102	US 1994-348150	19941128
			FR 1990-9778	A 19900731
			US 1991-737655	B2 19910730
			FR 1991-9908	A 19910802
			US 1993-923839	A3 19930803
			US 1994-240360	A3 19940510

PATENT FAMILY INFORMATION:

FAN 1993:539091

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 526348	A1	19930203	EP 1992-402213	19920803
	EP 526348	B1	19980218		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
				FR 1991-9908	A 19910802
	FR 2679903	A1	19930205	FR 1991-9908	19910802
	FR 2679903	B1	19931203		
	CA 2093221	A1	19930203	CA 1992-2093221	19920731
	CA 2093221	C	19980922		
				FR 1991-9908	A 19910802
	WO 9303013	A1	19930218	WO 1992-FR758	19920731
	W: AU, BR, CA, CS, FI, HU, JP, KR, NO, RU				
				FR 1991-9908	A 19910802
	AU 9224758	A	19930302	AU 1992-24758	19920731
	AU 658664	B2	19950427		
				FR 1991-9908	A 19910802
				WO 1992-FR758	A 19920731

ZA 9205781	A	19930302	ZA 1992-5781	19920731
			FR 1991-9908	A 19910802
BR 9205336	A	19931116	BR 1992-5336	19920731
			FR 1991-9908	A 19910802
			WO 1992-FR758	A 19920731
JP 06501960	T	19940303	JP 1993-503337	19920731
			FR 1991-9908	A 19910802
			WO 1992-FR758	W 19920731
LT 3064	B	19941025	LT 1992-114	19920731
			FR 1991-9908	A 19910802
LV 10091	B	19950420	LV 1992-87	19920731
			FR 1991-9908	A 19910802
HU 68927	A2	19950828	HU 1993-951	19920731
			FR 1991-9908	A 19910802
IL 102703	A	19970318	IL 1992-102703	19920731
			FR 1991-9908	A 19910802
JP 2633085	B2	19970723	JP 1992-503337	19920731
			FR 1991-9908	A 19910802
RU 2104268	C1	19980210	RU 1993-5168	19920731
			FR 1991-9908	A 19910802
			WO 1992-FR758	W 19920731
IL 117592	A	19990411	IL 1992-117592	19920731
			FR 1991-9908	A 19910802
			IL 1992-102703	A3 19920731
CZ 288173	B6	20010516	CZ 1993-682	19920731
			FR 1991-9908	A 19910802
			CS 1993-682	A 19920731
CA 2206776	C	20020226	CA 1992-2206776	19920731
			FR 1991-9908	A 19910802
			CA 1992-2093221	A3 19920731
SK 283463	B6	20030805	SK 1993-426	19920731
			FR 1991-9908	A 19910802
			WO 1992-FR758	W 19920731
AT 163289	T	19980315	AT 1992-402213	19920803
			FR 1991-9908	A 19910802
ES 2117038	T3	19980801	ES 1992-402213	19920803
			FR 1991-9908	A 19910802
NO 9301262	A	19930526	NO 1993-1262	19930401
NO 180047	B	19961028		
NO 180047	C	19970205		
			FR 1991-9908	A 19910802
			WO 1992-FR758	W 19920731
FI 104069	B	19991115	FI 1993-1476	19930401
FI 104069	B1	19991115		
			FR 1991-9908	A 19910802
			WO 1992-FR758	W 19920731
US 5481005	A	19960102	US 1994-348150	19941128
			FR 1990-9778	A 19900731
			US 1991-737655	B2 19910730
			FR 1991-9908	A 19910802
			US 1993-923839	A3 19930803
			US 1994-240360	A3 19940510
AU 9511541	A	19950504	AU 1995-11541	19950203
AU 691223	B2	19980514		
			FR 1991-9908	A 19910802
HU 9500474	A3	19951030	HU 1995-474	19950628
			FR 1991-9908	A 19910802
FI 9800175	A	19980127	FI 1998-175	19980127
FI 107048	B1	20010531		
			FR 1991-9908	A 19910802
			WO 1992-FR758	W 19920731
			FI 1993-1476	A 19930401

FAN 1995:777639

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI	US 5338755	A	19940816	US 1992-923839		19920803
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
	FR 2665441	A1	19920207	FR 1990-9778		19900731
	FR 2665441	B1	19921204			
	IL 114934	A	19960804	IL 1991-114934		19910730
				FR 1990-9778	A	19900731
				IL 1991-99012	A3	19910730
	HU 219351	B	20010328	HU 1971-99045		19910731
				FR 1990-9778	A	19900731
				HU 1991-2552	A	19910731
	FR 2679903	A1	19930205	FR 1991-9908		19910802
	FR 2679903	B1	19931203			
	AU 9224758	A	19930302	AU 1992-24758		19920731
	AU 658664	B2	19950427			
				FR 1991-9908	A	19910802
				WO 1992-FR758	A	19920731
	BR 9205336	A	19931116	BR 1992-5336		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	A	19920731
	JP 06501960	T	19940303	JP 1993-503337		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	RU 2104268	C1	19980210	RU 1993-5168		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	IL 117592	A	19990411	IL 1992-117592		19920731
				FR 1991-9908	A	19910802
				IL 1992-102703	A3	19920731
	CZ 288173	B6	20010516	CZ 1993-682		19920731
				FR 1991-9908	A	19910802
				CS 1993-682	A	19920731
	CA 2206776	C	20020226	CA 1992-2206776		19920731
				FR 1991-9908	A	19910802
				CA 1992-2093221	A3	19920731
	SK 283463	B6	20030805	SK 1993-426		19920731
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	NO 9301262	A	19930526	NO 1993-1262		19930401
	NO 180047	B	19961028			
	NO 180047	C	19970205			
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	FI 104069	B	19991115	FI 1993-1476		19930401
	FI 104069	B1	19991115			
				FR 1991-9908	A	19910802
				WO 1992-FR758	W	19920731
	US 5397801	A	19950314	US 1994-240360		19940510
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				US 1992-923839	A3	19920803
	US 5481005	A	19960102	US 1994-348150		19941128
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802
				US 1993-923839	A3	19930803
				US 1994-240360	A3	19940510
	US 5578633	A	19961126	US 1995-458614		19950602
				FR 1990-9778	A	19900731
				US 1991-737655	B2	19910730
				FR 1991-9908	A	19910802

				US 1992-923839	A3 19920803
				US 1994-240360	A3 19940510
				US 1994-348150	A3 19941128
FI 9800175	A	19980127		FI 1998-175	19980127
FI 107048	B1	20010531			
				FR 1991-9908	A 19910802
				WO 1992-FR758	W 19920731
				FI 1993-1476	A 19930401

OS MARPAT 116:214341

AB Title compds. [I; R1 = halo, alkyl, alkoxy, PhCH2O, etc.; R2 = (cyclo)alkyl, cycloalkenyl, (substituted) Ph; R3 = H, alkyl; R4 = CO2H, alkoxycarbonyl, CO2CH2Ph, (substituted) CONH2; R5 = alkyl, naphthyl, (substituted) Ph, etc.; m, n = 0-2] were prepared Thus, 4,2-Cl(R2CO)C6H3R (R2 = cyclohexyl) (II; R = NH2) was condensed with 1-naphthylsulfonyl chloride and the product condensed with BrCH2CO2Et to give II [R = N(CH2CO2Et)SO2R5; R5 = 1-naphthyl] which was treated with NaOMe/MeOH to give title compound III (cis and trans isomers). I had IC50 of .apprx.10-7M against oxytocin binding with a membrane preparation from pregnant rats.

IT 94107-57-0P 140916-44-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of vasopressin and oxytocin receptor ligands)

RN 94107-57-0 CAPLUS

CN Benzenesulfonamide, N-[2-(2-fluorobenzoyl)-4-nitrophenyl]-4-methyl- (9CI) (CA INDEX NAME)



RN 140916-44-5 CAPLUS

CN Benzenesulfonamide, N-[4-chloro-2-(2-fluorobenzoyl)phenyl]-4-nitro- (9CI) (CA INDEX NAME)



L24 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1990:79440 CAPLUS

DN 112:79440

TI Preparation of benzophenones as intermediates for fluorene phthalide dyes

IN Yanagihara, Naoto; Iwakura, Ken

PA Fuji Photo Film Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 01216942	A	19890830	JP 1988-41280	19880224
				JP 1988-41280	19880224

AB Benzophenones, useful as intermediates for fluorene phthalide dyes used in recording materials, are prepared by treatment of nitrobenzoyl chlorides with m-phenylenediamines in the presence of Lewis catalysts. p-Nitrobenzoyl chloride was treated with AlCl3 in 1,2-dichloroethane at room temperature for 1 h and treated with m-Et2NC6H4NHAc at room temperature for 5 h
to give 51% corresponding benzophenone derivative
IT 125317-21-7P
RL: IMF (Industrial manufacture); PREP (Preparation)
(preparation of, as intermediate for fluorene phthalide dyes)
RN 125317-21-7 CAPLUS
CN Benzenesulfonamide, N-[5-(diethylamino)-2-(4-nitrobenzoyl)phenyl]-4-methyl- (9CI) (CA INDEX NAME)



L24 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1989:477578 CAPLUS
DN 111:77578
TI Nucleophilic substitutions of bischloronitroso compounds. IV. Sulfonylamino oximes as extracting agents for copper(II)
AU Beger, J.; Neumann, R.; Gloe, K.; Muhl, P.
CS Sekt. Chem., Bergakad. Freiberg, Freiberg, DDR-9200, Ger. Dem. Rep.
SO Journal fuer Praktische Chemie (Leipzig) (1988), 330(5), 683-94
CODEN: JPCEAO; ISSN: 0021-8383
DT Journal
LA German
OS CASREACT 111:77578
AB RSO2NR1CR2R3CR4:NOH [I; R = Ph, 4-MeC6H4, Me, hexyl, 4-Me(CH2)4OC6H4; R1, R4 = H, Me; R2 = R3 = Me; R2 = H, R3R4 = (CH2)n, hexene-1,6-diyl, cyclopentane-1,3-diyl, decadiene-1,1-diyl; n = 3, 4, 6, 10] were obtained by treating RSO2NHR1 with ClCR2R3CHR4:NOH or ClCR2R3CHR4N(O):N(O)CHR4CR2R3Cl. 4-R5C6H4SO2NHC6H4(Bz)R6-2,4 [R5 = Et, OMe, OEt, O(CH2)4Me, O(CH2)9Me; R6 = H, NO2] were prepared by sulfonating the amines and were converted to their oximes. Several I extracted Cu efficiently from solution
IT 24042-91-9P 121779-69-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and oximation of)

RN 24042-91-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 121779-69-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methoxy- (9CI) (CA INDEX NAME)



L24 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1988:131304 CAPLUS
DN 108:131304
TI 2-Arylsulfonamidobenzophenones and -acetophenones and their oximes
IN Schewe, Tankred; Rapoport, Samuel Mitja; Beger, Joerg; Kuehn, Hartmut; Binte, Hans Joachim; Slapke, Juergen
PA VEB Fahlberg-List, Ger. Dem. Rep.
SO Ger. Offen., 44 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI DE 3544409	A1	19861016	DE 1985-3544409		19851216
			DD 1984-271462	A2	19841221
DD 251126	A1	19871104	DD 1984-271462		19841221
CH 670389	A5	19890615	CH 1985-5505		19851223
			DD 1984-271462	A	19841221

OS CASREACT 108:131304; MARPAT 108:131304
AB The title compds. (I; R = Me, Ph, p-substituted Ph; R1 = H, alkyl, alkoxy, amino, acylamino; R2 = H, halo, NO2, amino, acylamino; X = O, oximino) were prepared as lipoxygenase and cyclooxygenase inhibitors. Thus, 0.02 mol 2-(p-methoxybenzenesulfonamido)acetophenone in EtOH was treated with 0.044 mol NH2OH.HCl in pyridine and the mixture was refluxed for 3 h to give 90% I (R = Me, R1 = 4-MeO, X = NOH, R2 = H) which at 50 μM showed 80% inhibition of arachidonic acid-induced contractions in guinea pigs vs. 30% for benoxaprofen.
IT 107506-26-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cyclooxygenase and lipoxygenase inhibitor)
RN 107506-26-3 CAPLUS
CN Acetamide, N-[4-[[(2-benzoylphenyl)amino]sulfonyl]phenyl]- (9CI) (CA

INDEX NAME)



L24 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1984:34519 CAPLUS
DN 100:34519
TI Heterocyclic syntheses via carbanionically induced rearrangement reactions
AU Hellwinkel, Dieter; Lenz, Ruediger; Laemmerzahl, Frank
CS Org. Chem. Inst., Univ. Heidelberg, Heidelberg, D-6900/1, Fed. Rep. Ger.
SO Tetrahedron (1983), 39(12), 2073-84
CODEN: TETRAB; ISSN: 0040-4020
DT Journal
LA English
OS CASREACT 100:34519
AB The easily occurring [1.3]-migrations of sulfonyl and carbonyl functions to neighboring Ph anions can be utilized for ring expansions by one benzo unit when suitably tailored precursor heterocycles are used. Thus, 1,2-benzisothiazole dioxide I can be transformed into dibenzothiazepine dioxide II, whereas dibenzo- and 1,2,4-benzothiazin dioxides III and IV, resp., give rise to tribenzothiazocin dioxide V and dibenzothiadiazocine dioxide VI, resp. Unexpected formations of heterocyclic systems, namely, spiroisoindolobenzoxazinisobenzofuran VII, 3,1-benzoxazin VIII, and phenanthridinium salt IX took place when N-(2-bromo-4-methylphenyl)phthalimide, 2,4-BrMeC6H3NBz2, and o-PhC6H4NMeCOC6H4Me-p were reacted with Me3CLi.
IT 88312-94-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 88312-94-1 CAPLUS
CN Benzenesulfonamide, 2-amino-N-(2-benzoyl-4-methylphenyl)- (9CI) (CA INDEX NAME)



L24 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1980:639482 CAPLUS
DN 93:239482
TI 7-Amino-5-phenyl-1,4-3H-benzodiazepin-2-(1H)-one
IN Christensen, Svend Aage
PA A/S Dumex, Den.
SO Dan., 6 pp.
CODEN: DAXXAF
DT Patent

LA Danish
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI	DK 142030	B	19800811	DK 1971-1079		19710309
				GB 1970-13636	A	19700320
	SE 384859	C	19780921	SE 1971-3442		19710317
				GB 1970-13636	A	19700320
	NO 134158	C	19791019	NO 1971-1059		19710318
				GB 1970-13636	A	19700320

AB The title compound (I) was prepared by tosylating 2,4-Bz(O2N)C6H3NH2, reducing 2,4-Bz(O2N)C6H3NHSO2C6H4Me-4, treating the amine with phthalic anhydride, detosylating II (R = SO2C6H4Me-4), treating II (R = H) with phthalylglycyl chloride, and cyclizing II (R = phthalimidoacetyl) with N2H4.

IT 37020-30-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, with phthalic anhydride)

RN 37020-30-7 CAPLUS

CN Benzenesulfonamide, N-(4-amino-2-benzoylphenyl)-4-methyl- (9CI) (CA INDEX NAME)



IT 24042-91-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reduction of)

RN 24042-91-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)



L24 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1972:462035 CAPLUS
DN 77:62035
TI Benzophenone derivative and its conversion to a benzodiazepine derivative
IN Christensen, Svend Age
PA Aktieselskabet Dumex (Dumex Ltd.)
SO Brit., 5 pp.
CODEN: BRXXAA
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1274142		19720510	GB 1970-13636	19700320

AB 5-H2N(O2N)C6H3COPh was refluxed 1 hr with p-MeC6H4SO2Cl in pyridine to give 2,5-(p-MeC6H4SO2NH)(O2N)C6H3COPh, which was reduced by Fe to 2,5-(p-MeC6H4SO2NH)(H2N)C6H3COPh (I). Treating I with phthalic anhydride in xylene gave the phthalimide (II, R = p-MeC6H4SO2), which was hydrolyzed to the amine (II, R = H) (III). Reacting III with phthalylglycyl chloride gave the acetamide (II, R = phthalimidoacetyl), which cyclized in the presence of (NH2)2.H2O to give the benzodiazepine (IV).

IT 24042-91-9P 37020-30-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 24042-91-9 CAPLUS

CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)



RN 37020-30-7 CAPLUS

CN Benzenesulfonamide, N-(4-amino-2-benzoylphenyl)-4-methyl- (9CI) (CA INDEX NAME)



L24 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN

AN 1970:456144 CAPLUS

DN 73:56144

TI Antidiabetic dibenzo[c,g][1,2,6]thiadiazocines

PA Upjohn Co.

SO Brit., 10 pp.
CODEN: BRXXAA

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 1193917		19700603	GB 1968-15251	19680329
				US	19670516
	DE 1770289			DE	
	FR 1584277			FR	
	US 3534062		19701013	US	19670516

AB Title compds. (I), useful against anaphylaxis and as antidiabetic agents, as well as starting materials in the manufacture of bleaching agents, herbicides and disinfectants, were prepared Thus, 25 g 5,2-Cl(H2N)C6H3Bz

and 23.9 o-O2NC6H4SO2Cl in 50 ml pyridine was refluxed .apprx.1 hr to give 35.2 g 2'-benzoyl-4-chloro-2-nitrobenzenesulfonanilide, which was reduced (Fe powder) then treated with p-MeC6H4SO3H to give I (R = R1 = R2 = H, R3 = 2-Cl). Other I (.apprx.3) were prepared, and many other I were cited.

IT 20434-81-5P 20434-83-7P 20434-84-8P
20594-91-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 20434-81-5 CAPLUS
CN Benzenesulfonanilide, 2-amino-2'-benzoyl-4'-chloro- (8CI) (CA INDEX NAME)



RN 20434-83-7 CAPLUS
CN Benzenesulfonanilide, 2'-benzoyl-4,4'-dichloro-2-nitro- (8CI) (CA INDEX NAME)



RN 20434-84-8 CAPLUS
CN Benzenesulfonanilide, 2-amino-2'-benzoyl-4,4'-dichloro- (8CI) (CA INDEX NAME)



RN 20594-91-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-2-nitro- (9CI) (CA INDEX NAME)



L24 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1969:523960 CAPLUS
DN 71:123960
TI 2-Amino-5-nitrobenzophenone
IN Podesva, Ctirad; Kohan, Geza
PA Delmar Chemicals Ltd.
SO Ger. Offen., 11 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
PI DE 1811785	B2	19760122	DE 1968-1811785		19681129
DE 1811785	C3	19760902			
			CA 1967-6408	A	19671129
CA 904344	A	19720704	CA 1967-6408	A	19671129
NO 130475	B	19740909	NO 1968-4688		19681125
			CA 1967-6408	A	19671129
NL 6816857	A	19690602	NL 1968-16857		19681126
			CA 1967-6408	A	19671129
CH 512447	A	19710915	CH 1968-512447		19681126
			CA 1967-6408	A	19671129
US 3585238	A	19710615	US 1968-779623		19681127
			CA 1967-6408	A	19671129
SE 367185	B	19740520	SE 1968-16269		19681128
			CA 1967-6408	A	19671129
DK 129832	B	19741125	DK 1968-5815		19681128
			CA 1967-6408	A	19671129
SE 386667	B	19760816	SE 1968-386667		19681128
			CA 1967-6408	A	19671129
AT 289768	B	19710510	AT 1968-11630		19681129
			CA 1967-6408	A	19671129
CS 149650	B2	19730725	CS 1968-8172		19681129
			CA 1967-6408	A	19671129
FI 51473	B	19760930	FI 1968-3414		19681129
			CA 1967-6408	A	19671129
NO 130431	B	19740902	NO 1970-1966		19700522
			CA 1967-6408	A	19671129
			NO 1968-4688	A	19681125

AB The title compound (I) was prepared in good yield, without using unduly high temperature or high pressure. A mixture of 104.6 g. 2-chloro-5-nitrobenzophenone, 231.6 g. Na salt of p-MeC6H4-SO2NH2, and 500 ml. HCONMe2 was heated at 160-70° with stirring 6 hrs., the mixture cooled, poured into 2 kg. ice and extracted with CHCl3, the extract washed with water, and the solvent distilled to give 2-(p-toluenesulfonamido)-5-nitrobenzophenone (II), m. 123-5° (MeOH). II (122.5 g.) was hydrolyzed by concentrated H2SO4 at .apprx.55° 30 min. to yield I, m. 162-3° (C6H6). Reaction of I with phthalimidoacetyl chloride and treatment of the product with N2H4.H2O gave 7-nitro-5-phenyl-3H-1,4-benzodiazepin-2(1H)-one, a very important psychotropic agent with relatively low toxicity.

IT 24042-91-9P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 24042-91-9 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-nitrophenyl)-4-methyl- (9CI) (CA INDEX NAME)



L24 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1968:477247 CAPLUS
DN 69:77247
TI Preparation of 2H-1,2,3-benzothiadiazine 1,1-dioxides, 11H-11,11a-dihydrobenzimidazo[1,2-b][1,2]benzisothiazole 5,5-dioxides, 6H-dibenzo[c,g][1,2,5]thiadiazocine 5,5-dioxides and 5H-dibenzo[c,g][1,2,6]thiadiazocine 6,6-dioxides
AU Wright, John B.
CS Upjohn Co., Kalazoo, MI, USA
SO Journal of Heterocyclic Chemistry (1968), 5(4), 453-9
CODEN: JHTCAD; ISSN: 0022-152X
DT Journal
LA English
OS CASREACT 69:77247
AB o-Benzoylbenzenesulfonyl chlorides (I) were prepared conveniently from aminobenzophenones by diazotization followed by reaction with SO2 in the presence of Cu+, according to the general method of Meerwein. Reaction of I with hydrazine led to 4-phenyl-2H-1,2,3-benzothiadiazine 1,1-dioxides, which could be methylated and acetylated readily in the 2-position. The 2-methyl derivative was prepared by reaction of I with methylhydrazine. Catalytic hydrogenation of 6-chloro-4-phenyl-2H-1,2,3-benzothiadiazine 1,1-dioxide gave the 3,4-dihydro derivative Reaction of I with o-phenylenediamine followed by cyclodehydration gave 11H-11,11a-dihydrobenzimidazo[1,2-b]-[1,2]benzoisothiazole 5,5-dioxides (II). One of the II derivs. in NaOH solution in the presence of MeI or benzyl chloride was transformed into 6-methyl- and 6-benzyl-5H-dibenzo[c,g]1,2,6]thia diazocine 5,5-dioxide (III), resp. 5H-Dibenzo[c,g] [1,2,6]thiadiazocine 6,6-dioxides were prepared also by cyclodehydration of 2-amino-2'-benzoylbenzenesulfonanilides.
IT 20434-81-5P 20434-83-7P 20434-84-8P
20594-91-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 20434-81-5 CAPLUS
CN Benzenesulfonanilide, 2-amino-2'-benzoyl-4'-chloro- (8CI) (CA INDEX NAME)



RN 20434-83-7 CAPLUS
CN Benzenesulfonanilide, 2'-benzoyl-4,4'-dichloro-2-nitro- (8CI) (CA INDEX NAME)



RN 20434-84-8 CAPLUS
CN Benzenesulfonanilide, 2-amino-2'-benzoyl-4,4'-dichloro- (8CI) (CA INDEX NAME)



RN 20594-91-6 CAPLUS
CN Benzenesulfonamide, N-(2-benzoyl-4-chlorophenyl)-2-nitro- (9CI) (CA INDEX NAME)



L24 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1953:27210 CAPLUS
DN 47:27210
OREF 47:4622h-i,4623a-d
TI Anthraquinone vat dyes
PA C I B A Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 680857		19521015	GB 1950-18322	19500721

AB A new series of anthraquinone vat dyes suitable for drying and printing cellulose fibers is obtained by heating 2 mols. 1,4-diaminoanthraquinonyl 2-aryl ketone with 1 mol. of an aromatic dicarboxylic acid dichloride. Thus, fluoranthenedicarboxylic acid dichloride (I) 3.2, 1,4-diamino-2-(p-chlorobenzoyl)anthraquinone (II) 8, quinoline 5, and pyridine 5 in C6H3Cl3 225 parts, heated with stirring during 3 hrs. up to

160° followed by further heating for 0.5 hr., gave gray needles, yellowish olive in concentrated H2SO4, dyes cotton from an olive-green vat bluish gray tints fast to Cl, boiling, and light, and having a very high tinctorial strength in printing. An analogous new dye was obtained from I and the 3,4-dichlorobenzoyl analog of II, dyes vegetable fibers from a green vat bluish gray tints. Similar vat dyes were prepared by condensing similarly 3,9-benzanthronedicarboxylic acid dichloride (from the acid and SOCl2) with II, dyes gray tints from an olive-green vat; and (p-ClCOC6H4)2 with II, dyes cotton very fast reddish blue tints. To 1,4-dichloro-2-anthraquinonecarbonyl chloride (III) 34 and pyrene 20 in o-C6H4Cl2 250 was slowly added with stirring at 40-50° AlCl3 55, the mixture stirred 2 hrs. at 40-50° and then 1 hr. at 60-5° and decomposed with ice and HCl, the solvent removed by steam distillation, and the residue filtered off and washed with dilute aqueous Na2CO3 to leave 1,4-dichloro-2-(3-pyrenoyl)anthraquinone (IV), 47 parts, brown powder, m. 249° (from o-C6H4Cl2). IV 15, p-MeC6H4SO2NH2 140, NaOAc 22, Cu(OAc)2 0.5, and CuCl 0.5 parts, heated with stirring 1 hr. at 170-5°, and the mixture poured into H2O and boiled gave 1,4-bis(p-tolylsulfonamido)-2-(3-pyrenoyl)anthraquinone (V), brown crystalline powder. V 17 stirred 10 hrs. at 0-5° with 99% HF 150 parts, and the mixture diluted with ice and H2O gave 1,4-diamino-2-(3-pyrenoyl)-anthraquinone (VI), green-blue crystalline powder from PhCl, soluble in Me2CO with a blue color. 1,4-Diamino-2-naphthoylanthraquinone (VII), was prepared by a similar sequence of reactions from III 69, C10H8 150, and AlCl3 81 in o-C6H4Cl2 150 parts, via 1,4-dichloro-2-naphthoylanthraquinone, m. 214° (from o-C6H4Cl2-toluene). Vat dyes were also obtained by the condensation of VII and I, blue-gray dyeing from a dull green vat; VII and (m-HO2CC6H4N:)2, blue dyeing from a green-olive vat; and VI and (p-HO2CC6H4N:)2, gray dyeing from a green-olive vat.

IT 874514-29-1P, p-Toluenesulfonamide, N,N'[2-(3-pyrenylcarbonyl)-1,4-anthraquinonylene]bis-
RL: PREP (Preparation)
(preparation of)

RN 874514-29-1 CAPLUS

CN p-Toluenesulfonamide, N,N'[2-(3-pyrenylcarbonyl)-1,4-anthraquinonylene]bis- (5CI) (CA INDEX NAME)

PAGE 1-A





L24 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1952:53273 CAPLUS
DN 46:53273
OREF 46:8866b-h
TI Bis(1,4-diamino-2-arylcarbonylanthraquinone)amides of aromatic dicarboxylic acids
IN Moergeli, Eduard
PA C I B A Ltd.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2598587		19520527	US 1950-174362	19500717

AB Vat dyes are prepared by treating 2 mols. of a 1,4-diamino-2-anthraquinonyl 2-aryl ketone, of which the aryl radical may contain substituents, with one mol. of a reactive derivative of an aromatic dicarboxylic acid. A mixture of 3.2 parts of fluoranthenedicarbonyl dichloride (I) (British patent 533,963 (C.A. 36, 1190.7)), 1,4-diamino-2-(p-chlorobenzoyl)anthraquinone (II) 8, quinoline 5, pyridine 5, and 225 parts by volume of trichlorobenzene (III) are heated to 160° while stirring in the course of 3 hrs. Stirring is continued 1/2 hr. and a dye seps. in the form of gray needles. The dye is soluble in concentrated H_2SO_4 with a yellowish olive color; dyes cotton from an olive-green vat a blueish gray tint which is fast to Cl, boiling, and light, and has a good strength in prints. I similarly reacts with 1,4-diamino-2-(3,4-dichlorobenzoyl)anthraquinone in a mixture of quinoline and III at 160° to give a more bluish tinted gray dye than that above. 6-bz-1-Benzanthronedicarbanyl dichloride and 1,4-diamino-2-(p-chlorobenzoyl)anthraquinone gives a dye coloring cotton fast gray tints from an olive-green vat. 4,4'-Biphenyldicarbonyl chloride (IV) and 1,4-diamino-2-(p-chlorobenzoyl)anthraquinone give a cotton vat dye of reddish blue tint. Use of terephthalic acid dichloride in place of IV in the last example gives a blue dye. Other vat dyes prepared from 2 mols of an anthraquinone component and 1 mol. of acid component are as follows: II and 4,4'-azobenzenedicarboxylic acid (V) give a gray; II and 3,3'-azobenzenedicarboxylic acid (VI) give a reddish blue; II and 2,6-naphthalenedicarboxylic acid give a reddish blue; II and thianthrenedicarboxylic acid (U.S. patent 2,338,516 (C.A. 38, 3851.2)) give a reddish blue; II and 2,6-benzanthronedicarboxylic acid give a reddish blue-gray; II and 2,-8-chrysenedicarboxylic acid give a violet-gray; 1,4-di-amino-2-benzoylanthraquinone and I give a bluish gray; 1,4-diamino-2-p-toluylanthraquinone and I give a gray; 1,4-diamino-2-anisoylanthraquinone and I give a gray; 1,4-diamino-2-naphthoylanthraquinone (VII) and I give a blue-gray; VII and VI give a blue; 1,4-diamino-2-(3-pyrenoyl)-anthraquinone (VIII) and V give a gray. VIII is prepared as follows: 1,4-dichloro-2-(3-pyrenecarbonyl)anthraquinone (IX), brown powder, m. 249° (after crystallization from o-dichlorobenzene) is prepared by the action of $AlCl_3$ on 1,4-dichloro-2-anthraquinonecarbonyl chloride (X) and pyrene. IX 15 parts, p-toluenesulfonamide (XI) 140,

NaOAc 22, Cu(OAc)2 0.5, and Cu2Cl2 0.5 are heated 1 hr. at 170-5°, the water-soluble constituents are extracted with boiling water. The product is crystallized from aqueous pyridine to give a brown crystallization powder of 1,4-bis(p-tolylsulfonamido)-2-(3-pyrenecarbonyl)anthraquinone (XII). XII 17 is hydrolyzed in 99% HF 150 by stirring 10 hrs. at 0-5°. VIII is then precipitated by addition of ice and water and is purified by extracting with boiling aqueous NH3 NH3 solution; then crystallizing from chlorobenzene. VIII is an acetone-soluble, blue-green crystallization powder. VII is prepared by the action of AlCl3 on X and naphthalene to give, first 1,4-dichloro-2-naphthoylanthraquinone, m. 214°, which is then treated as above with XI and then hydrolyzed to give VII.

IT 874514-29-1P, p-Toluenesulfonamide, N,N'[2-(3-pyrenylcarbonyl)-1,4-anthraquinonylene]bis-
RL: PREP (Preparation)
(preparation of)

RN 874514-29-1 CAPLUS

CN p-Toluenesulfonamide, N,N'[2-(3-pyrenylcarbonyl)-1,4-anthraquinonylene]bis- (5CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A